US20110160459A1 - 5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists - Google Patents

5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists Download PDF

Info

Publication number
US20110160459A1
US20110160459A1 US13/042,620 US201113042620A US2011160459A1 US 20110160459 A1 US20110160459 A1 US 20110160459A1 US 201113042620 A US201113042620 A US 201113042620A US 2011160459 A1 US2011160459 A1 US 2011160459A1
Authority
US
United States
Prior art keywords
compound
alkyl
dihydro
nmr
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/042,620
Inventor
Josephus H.M. Lange
Hicham Zilaout
Bernard J. Van Vliet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Priority to US13/042,620 priority Critical patent/US20110160459A1/en
Publication of US20110160459A1 publication Critical patent/US20110160459A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

  • the present disclosure relates to the fields of pharmaceutical and organic chemistry, and provides 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives, intermediates for synthesizing these compounds, formulations comprising these compounds, and methods of treatment using these compounds.
  • pyrazoline 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole
  • the endogenous cannabinoid receptor agonist, anandamide, is too unstable to be of practical value as a drug.
  • Other endocannabinoids such as 2-arachidonoyl-glycerol and noladin ether.
  • ⁇ 9 -tetrahydrocannabinol ⁇ 9 -THC, dronabinol, Marinol®
  • Nabilone Cesamet®
  • Sativex® an extract from the Cannabis sativa L. plant
  • Compounds like CP 55,940 and WIN 55, 212-2 are not registered drugs, but have been, and still are, used as pharmacological tools.
  • cannabinoid CB 1 receptors can occur in two different states: the active ‘R*-state’ to which agonists bind, and the inactive ‘R-state’ to which antagonists or inverse agonists—such as rimonabant—bind. Both states have considerably different three-dimensional geometries.
  • Key interaction in the cannabinoid-CB 1 receptor model is a hydrogen bond between the carbonyl group of, e.g., the CB 1 receptor inverse agonist rimonabant, and the LYS192 residue of the CB 1 receptor.
  • This hydrogen bond has a stabilizing effect on the Lys192-Asp366 salt bridge of the intracellular end of the transmembrane helices 3 and 6.
  • the existence of this specific salt bridge is induced by a pronounced kink at Pro 358 in transmembrane helix 6, present in the inactive R-state of the receptor, but not in the active R*-state, which is stabilized by CB 1 receptor agonist binding (Hurst, 2002; Shim, 2002; Reggio, 2003; Pertwee, 2005 and Lange, 2005).
  • CB 1 receptor agonist binding Hurst, 2002; Shim, 2002; Reggio, 2003; Pertwee, 2005 and Lange, 2005.
  • cannabinoid receptor agonists have therapeutic possibilities as appetite stimulants, enti-emetics, analgesics, anti-glaucoma agents (Croxford, 2003; Drysdale, 2003), tumor growth inhibitors (Ligresti, 2003), and agents for the treatment of neurodegenerative disorders, including multiple sclerosis and Alzheimer's disease (Smith, 2004; Croxford, 2004).
  • the invention relates to compounds of formula (I):
  • R 1 is chosen from:
  • R 2 is chosen from aryl and heteroaryl, each of which may be optionally substituted with 1-5 substituents Y as defined above;
  • R 3 is chosen from:
  • R 4 is chosen from hydrogen and C 1-4 alkyl
  • R 5 is chosen from hydrogen and C 1-2 alkyl, optionally substituted with 1-3 fluorine atoms;
  • R 6 is chosen from hydrogen and C 1-2 alkyl, optionally substituted with 1-3 fluorine atoms.
  • the invention relates to compounds of formula (I):
  • R 1 is chosen from:
  • R 2 is chosen from phenyl, thienyl, benzothienyl, and pyridyl, each of which may be optionally substituted with 1 or 2 substituents, wherein the substituents are the same or different, and are chosen from halogen, methyl, CF 3 , OCH 3 , and OCF 3 ;
  • R 3 is chosen from:
  • R 4 , R 5 , and R 6 are as defined above.
  • the invention relates to compounds of formula (I):
  • R 1 is chosen from:
  • R 2 is chosen from phenyl, thienyl, benzothienyl, and pyridyl, each of which may be optionally substituted with halogen, methyl, CF 3 , OCH 3 , and OCF 3 ; and
  • R 3 , R 4 , R 5 , and R 6 are as defined above.
  • the invention relates to compounds of formula (I):
  • R 1 is chosen from 2-cyano-ethyl, n-propyl, n-butyl, 4,4,4-trifluorobutyl, isobutyl, n-pentyl, cyclohexylmethyl, and phenethyl;
  • R 2 is chosen from 2-fluorophenyl, 3-(trifluoromethyl)phenyl, 3-chlorophenyl, 3-fluorophenyl, 3-methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, benzothien-3-yl, pyrid-2-yl, thien-3-yl, and phenyl;
  • R 3 is chosen from 3-(trifluoromethyl)benzyl, 3-(trifluoromethyl)benzyl, 1-(4-fluorophenyl)-1-methyl-ethyl, 1-phenyl-1-methyl-ethyl, 1-phenyl-ethyl, 2-indanyl, 2-(4-fluorophenyl)-1,1-dimethyl-ethyl, 2-(trifluoromethyl)benzyl, 2,2-dimethylpropyl, 2,2-diphenylethyl, 2,2-diphenylpropyl, 2-methoxybenzyl, 2-phenyl-propyl, 2-phenyl-trans-cyclopropyl, 2-trifluoromethyl)phenyl, 3,4,5-trimethoxybenzyl, 3,4-dimethoxybenzyl, 3-fluorobenzyl, 3-methoxybenzyl, 4-chlorobenzyl, 4-methoxybenzyl, 5-methyl-thiazol-2-yl, adamant-1
  • R 4 is chosen from hydrogen and methyl
  • R 5 is chosen from hydrogen and methyl
  • R 6 is hydrogen
  • the invention relates to compounds of formula (I):
  • the invention relates to compounds of formula (I):
  • the invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, for the treatment of disorders in which cannabinoid receptors are involved, and in addition, that can be treated via manipulation of those receptors.
  • the invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, for the treatment of multiple sclerosis, traumatic brain injury, pain including chronic pain, neuropathic pain, acute pain and inflammatory pain, osteoporosis, appetite disorders, epilepsy, Alzheimer's disease, Tourette's syndrome, cerebral ischaemia and gastrointestinal disorders.
  • compositions for treating for example, at least one disorder or condition that may be treated by activating at least one cannabinoid CB 1 receptor, the compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier;
  • methods of treatment of at least one disorder or condition that may be treated by activating at least one cannabinoid CB 1 receptor comprising administering to a mammal in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof;
  • compositions for treating for example, at least one disorder or condition chosen multiple sclerosis, traumatic brain injury, pain including chronic pain, neuropathic pain, acute pain and inflammatory pain, osteoporosis, appetite disorders, epilepsy, Alzheimer's disease, Tourette's syndrome, cerebral ischaemia and gastrointestinal disorders;
  • compositions for treatment of at least one disorder or condition chosen from the disorders listed herein comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier;
  • methods of treatment of at least one disorder or condition that may be treated by activating at least one cannabinoid CB 1 receptor comprising administering to a patient in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof;
  • methods of antagonizing at least one cannabinoid CB 1 receptor which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I).
  • the invention also provides for the use of at least one compound or salt according to formula (I) for the manufacture of a medicament.
  • the invention further relates to combination therapies wherein at least one compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.
  • Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the compounds of the invention.
  • the invention also provides compounds, pharmaceutical compositions, kits and methods for the treatment of a disorder or condition that may be treated by activating at least one cannabinoid CB 1 receptor, the method comprising administering to a patient in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also provides methods of preparing the compounds of the invention and the intermediates used in those methods.
  • Isolation and purification of the compounds and intermediates described herein can be affected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography, or a combination of these procedures.
  • suitable separation and isolation procedures can be taken from the preparations and examples. However, other equivalent separation or isolation procedures could, of course, also be used.
  • the compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.
  • All compounds of the present invention do contain at least one chiral center (at the 5-position of the 4,5-dihydropyrazole ring). Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention.
  • Cis and trans isomers of the compounds of formula (I) or of pharmaceutically acceptable salts thereof are also within the scope of the invention, and this also applies to tautomers of the compounds of formula (I) or pharmaceutically acceptable salts thereof.
  • Some of the crystalline forms for the compounds may exist as polymorphs, and as such are intended to be included in the present invention.
  • some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
  • Isotopically-labeled compounds of formula (I) or pharmaceutically acceptable salts thereof including compounds of formula (I) isotopically-labeled to be detectable by PET or SPECT, are also included within the scope of the invention, and the same applies to compounds of formula (I) labeled with [ 13 C]—, [ 14 C]—, [ 3 H]—, [ 18 F]—, [ 125 I]— or other isotopically enriched atoms, suitable for receptor binding or metabolism studies.
  • the compounds of the invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction and disease.
  • alkyl denotes a univalent saturated branched or straight hydrocarbon chain. Unless otherwise stated, such chains can contain from 1 to 18 carbon atoms.
  • Representative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, and the like.
  • the alkyl group When qualified as ‘lower’, the alkyl group will contain from 1 to 6 carbon atoms. The same carbon content applies to the parent term ‘alkane’, and to derivative terms such as ‘alkoxy’.
  • the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C x -C y defines the number of carbon atoms present from the integer “x” to the integer “y” inclusive.
  • Alkyl(C 1-3 ) for example, means methyl, ethyl, n-propyl or isopropyl
  • alkyl(C 1-4 ) means ‘methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl’.
  • alkeny denotes straight or branched hydrocarbon radicals having one or more carbon-carbon double bonds, such as vinyl, allyl, butenyl, etc., and for example comprises (C 2-4 ) alkenyl.
  • alkynyl groups the straight or branched hydrocarbon radicals have one or more carbon-carbon triple bonds, such as ethynyl, propargyl, 1-butynyl, 2-butynyl, etc., and e.g. includes (C 2-4 ) alkynyl.
  • alkenyl’ and ‘alkynyl chains can contain from 1 to 18 carbon atoms.
  • acyl comprises alkyl(C 1-3 ) carbonyl, arylcarbonyl or aryl-alkyl(C 1-3 )carbonyl.
  • Aryl embraces mono- or polycyclic aromatic groups, including phenyl, naphthyl, 1,2,3,4-tetrahydro-naphtyl, indenyl, fluorenyl, anthracenyl, phenanthrenyl, naphthacenyl and azulenyl.
  • Heteroaryl embraces mono- or polycyclic hetero-aromatic, including furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, imidazo[2,1-b][1,3]thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, indazolyl, indolyl, indolizinyl, isoindolyl, benzo[b]furanyl, 1,2,3,4-tetrahydroiso-quinolinyl, indanyl, indenyl, benzo[b]thienyl, 2,3-dihydro-1,4-benzodioxin-5-yl, benzimidazolyl, cinnolinyl, carbazolyl, acriterio
  • Halo or ‘Halogen’ means chloro, fluoro, bromo or iodo; ‘hetero’ as in ‘heteroalkyl, heteroaromatic’ etc. means containing one or more N, O or S atoms. ‘heteroalkyl’ includes alkyl groups with heteroatoms in any position, thus including N-bound O-bound or S-bound alkyl groups.
  • substituted means that the specified group or moiety bears one or more substituents. Where any group may carry multiple substituents, and a variety of possible substituents is provided, the substituents are independently selected, and need not to be the same.
  • unsubstituted means that the specified group bears no substituents.
  • substituents the term “independently” means that when more than one of such substituents are possible, they may be the same or different from each other.
  • C 3-8 -cycloalky means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
  • C 5-8 heterocycloalkyl refers to heteroatom containing rings including but not limited to piperidinyl, morpholinyl, azepanyl, pyrrolidinyl, thiomorpholinyl, piperazinyl, tetrahydrofuryl, tetrahydropyranyl;
  • C 5-10 bicycloalkyl group refers to carbo-bicyclic ring systems including but not limited to bicyclo[2.2.1]heptanyl, bicyclo[3.3.0]octanyl or the bicyclo[3.1.1] heptanyl group;
  • C 6-10 -tricycloalkyl group refers to carbo-tricyclic ring systems including but not limited to the 1-adamantyl, noradaman
  • oxy refers to an oxygen atom, a sulphur atom and a carbonyl (C ⁇ O) group, serving as linker between two groups, such as for instance hydroxyl, oxyalkyl, thioalkyl, carboxyalkyl, etc.
  • amino refers to a nitrogen atom that may be either terminal, or a linker between two other groups, wherein the group may be a primary, secondary or tertiary (two hydrogen atoms bonded to the nitrogen atom, one hydrogen atom bonded to the nitrogen atom and no hydrogen atoms bonded to the nitrogen atom, respectively) amine.
  • sulfinyl and sulfonyl as used herein as part of another group respectively refer to an —SO— or an —SO 2 — group.
  • the terms ‘compound’ or ‘compounds’ include tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmacologically acceptable salts, also when not explicitly mentioned.
  • the term “leaving group” shall mean a charged or uncharged atom or group that departs during a substitution or displacement reaction.
  • the term refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile.
  • Such leaving groups are well known in the art (Smith, 2001). Examples include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides (Br, Cl, I), triflates, mesylates, tosylates, and the like.
  • N-oxides of the compounds mentioned above belong to the invention.
  • Tertiary amines may or may not give rise to N-oxide metabolites. The extent to what N-oxidation takes place varies from trace amounts to a near quantitative conversion.
  • N-oxides may be more active than their corresponding tertiary amines, or less active. Whilst N-oxides can easily be reduced to their corresponding tertiary amines by chemical means, in the human body this happens to varying degrees.
  • Some N-oxides undergo nearly quantitative reductive conversion to the corresponding tertiary amines, in other cases conversion is a mere trace reaction, or even completely absent (Bickel, 1969).
  • Form is a term encompassing all solids: polymorphs, solvates, amorphous forms.
  • Crystal form refers to various solid forms of the same compound, for example polymorphs, solvates and amorphous forms.
  • Cocrystals are multicomponent crystals with a unique lattice: new chemical species produced with neutral compounds.
  • Amorphous forms are non-crystalline materials with no long range order, and generally do not give a distinctive powder X-ray diffraction pattern. Crystal forms in general have been described by Byrn (1995) and Martin (1995).
  • Polymorphs are crystal structures in which a compound can crystallize in different crystal packing arrangements, all of which have the same elemental composition.
  • Polymorphism is a frequently occurring phenomenon, affected by several crystallization conditions such as temperature, level of supersaturation, the presence of impurities, polarity of solvent, rate of cooling.
  • Different polymorphs usually have different X-ray diffraction patterns, solid state NMR spectra, infrared or Raman spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate.
  • the compounds of formula (I) While it may be possible for the compounds of formula (I) to be administered as the raw chemical, in at least one embodiment, they are presented in a ‘pharmaceutical composition’.
  • the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers thereof, and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be ‘acceptable’ in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • composition encompasses a product comprising specified ingredients in predetermined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts.
  • this term encompasses a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the pharmaceutical composition includes enough of the active object compound to produce the desired effect upon the progress or condition of diseases.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the term ‘combination preparation’ comprises both true combinations, meaning a compound of formula (I) and other medicaments physically combined in one preparation such as a tablet or injection fluid, as well as ‘kit-of-parts’, comprising a compound of formula (I) and another medicament in separate dosage forms, together with instructions for use, optionally with further means for facilitating compliance with the administration of the component compounds, e.g., label or drawings.
  • the pharmacotherapy by definition is simultaneous.
  • the contents of ‘kit-of-parts’ can be administered either simultaneously or at different time intervals. Therapy being either concomitant or sequential will be dependant on the characteristics of the other medicaments used, characteristics like onset and duration of action, plasma levels, clearance, etc., as well as on the disease, its stage, and characteristics of the individual patient.
  • the affinity of the compounds of the invention for cannabinoid CB 1 receptors was determined as described below. From the binding affinity measured for a given compound of formula (I), one can estimate a theoretical lowest effective dose. At a concentration of the compound equal to twice the measured K i -value, nearly 100% of the cannabinoid CB 1 receptors likely will be occupied by the compound. Converting that concentration to mg of compound per kg of patient—assuming ideal bioavailability—results in a theoretical lowest effective dose. Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dose of the compound to be administered will depend on the relevant indication, the age, weight and sex of the patient and may be determined by a physician.
  • the dosage may be in amounts, for example from 0.01 mg/kg to 10 mg/kg.
  • the typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician.
  • total daily dose administration to a patient in single or individual doses may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily, and more usually from 0.01 to 1,000 mg per day, of total active ingredients.
  • Such dosages will be administered to a patient in need of treatment from one to three times each day, or as often as needed for efficacy, and for periods of at least two months, more typically for at least six months, or chronically.
  • terapéuticaally effective amount refers to an amount of a therapeutic agent to treat a condition treatable by administrating a composition of the invention. That amount is the amount sufficient to exhibit a detectable therapeutic or ameliorative response in a tissue system, animal or human. The effect may include, for example, treating the conditions listed herein.
  • the precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician (researcher, veterinarian, medical doctor or other clinician), and the therapeutics, or combination of therapeutics, selected for administration. Thus, it is not useful to specify an exact effective amount in advance.
  • a “pharmaceutical salt” refers to an acid:base complex containing an active pharmaceutical ingredient (API) along with additional non-toxic molecular species in the same crystal structure.
  • pharmaceutically acceptable salt refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well-known in the art. They can be prepared in situ when finally isolating and purifying the compounds of the invention, or separately by reacting them with pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids (Berge, 1977).
  • Common anions used in pharmaceutically acceptable salts include: chloride, bromide, sulfate, nitrate, phosphate, bicarbonate, mesylate, esylate, isothianate, tosylate, napsylate, besylate, acetate, propionate, maleate, benzoate, salicylate, fumarate, citrate, lactate, maleate, tartrate, pamoate, succinate, glycolate, hexanoate, octanoate, decanoate, stearate, oleate, aspartate and glutamate.
  • Common cations used as counterions in pharmaceutically acceptable salts include: sodium, potassium, calcium, magnesium, lithium, zinc, aluminum, arginine, lysine, histidine, triethylamine, ethanolamine, triethanolamine, ethilenediamine, meglumine, procaine and benzathine.
  • the ‘free base’ form may be regenerated by contacting the salt with a base or acid, and isolating the parent compound in the conventional matter.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • treatment refers to any treatment of a mammalian, for example human condition or disease, and includes: (1) inhibiting the disease or condition, i.e., arresting its development, (2) relieving the disease or condition, i.e., causing the condition to regress, or (3) stopping the symptoms of the disease.
  • inhibit includes its generally accepted meaning which includes restraining, alleviating, ameliorating, and slowing, stopping or reversing progression, severity, or a resultant symptom.
  • medical therapy intends to include diagnostic and therapeutic regimens carried out in vivo or ex vivo on humans or other mammals.
  • mammals include animals of economic importance such as bovine, ovine, and porcine animals, especially those that produce meat, as well as domestic animals, sports animals, zoo animals, and in at least one embodiment humans.
  • subject refers to an animal, in at least one embodiment, a mammal, for example a human, who has been the object of treatment, observation or experiment.
  • Sepacore chromatographic separations were carried out using Supelco equipment, VersaFLASHTM columns, VersaPakTM silica cartridges, Büchi UV monitor C-630, Büchi Pump module C-605, Büchi fraction collector C-660 and Büchi pump manager C-615. Melting points were recorded on a Buchi B-545 melting point apparatus or determined by DSC (differential scanning calorimetry) methods. Optical rotations ([ ⁇ ] D ) were measured on an Optical Activity polarimeter. Specific rotations are given as deg/dm, the concentration values are reported as g/100 mL of the specified solvent and were recorded at 23° C., unless indicated otherwise.
  • a hydrazone derivative of general formula (II) wherein R 1 has the abovementioned meaning and R 7 is a C 1-3 alkyl group, such as an ethyl group, can be obtained from a compound of general formula R 1 NHNH 2 and ethylglyoxalate.
  • a hydrazone derivative of general formula (II) can be reacted with a chlorinating agent such as tert-butyl hypochlorite or N-chlorosuccinimide (NCS) in an inert solvent to give a compound of general formula (III).
  • a compound of general formula (III) wherein R 1 has the abovementioned meaning, and R 7 is a C 1-3 alkyl group can be reacted with a compound of general formula (IV), wherein R 2 , R 5 and R 6 have the above-mentioned meaning, to give a compound of general formula (V) wherein R 1 , R 2 , R 5 , R 6 and R 7 have the abovementioned meaning.
  • a compound of general formula (V) can be reacted with a base such as aqueous potassium hydroxide or lithium hydroxide to give a carboxylic acid derivative of general formula (VI), or a sodium, potassium, lithium or cesium salt thereof, wherein R 1 , R 2 , R 5 and R 6 have the abovementioned meaning.
  • a base such as aqueous potassium hydroxide or lithium hydroxide to give a carboxylic acid derivative of general formula (VI), or a sodium, potassium, lithium or cesium salt thereof, wherein R 1 , R 2 , R 5 and R 6 have the abovementioned meaning.
  • a compound of general formula (VI) can be reacted with an amine of general formula R 3 R 4 NH, wherein R 3 and R 4 have the abovementioned meaning, in the presence of an activating or coupling reagent such as 2-chloro-1,3-dimethylimidazolinium hexafluorophosphate (CIP), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) or O-benzotriazol-1-yl-N,N,N′,N′-tetramethyl-uronium hexafluorophosphate (HBTU) in an inert organic solvent such as dichloromethane to give a compound of general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the abovementioned meaning.
  • a base such as triethylamine or Hünigs base (DIPEA
  • an ester derivative having formula (V) can be reacted in a so-called Weinreb amidation reaction with an amine of general formula R 3 R 4 NH to give a compound of general formula (I).
  • Such Weinreb amidation reactions can be promoted by the use of trimethylaluminum Al(CH 3 ) 3 (For more information on aluminum-mediated conversion of esters to amides, see Levin, 1982).
  • Another alternative is to chlorinate a carboxylic acid derivative having formula (VI) to the corresponding acid chloride (Va) wherein R 8 is a chloro atom using a chlorinating agent such as thionyl chloride (SOCl 2 ) or oxalyl chloride.
  • the formed acid chloride derivative can subsequently be reacted with an amine of general formula R 3 R 4 NH to give a compound of general formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the abovementioned meaning.
  • the invention relates to compounds of formula (Va):
  • R 1 , R 2 , R 5 and R 6 have the abovementioned meaning and R 8 is chosen from chloro and OR 7 , where R 7 is C 1-3 alkyl, provided that if R 2 is phenyl and R 1 is benzyl, then R 7 is not ethyl.
  • R 7 is C 1-3 alkyl, provided that if R 2 is phenyl and R 1 is benzyl, then R 7 is not ethyl.
  • the invention relates to compounds of formula (VI):
  • R 1 , R 2 , R 5 and R 6 have the same meanings as given above, provided that if R 2 is phenyl, then R 1 is not benzyl.
  • Such compounds are useful in the synthesis of compounds of the general formula (I).
  • a compound of general formula (I) wherein R 5 and R 6 are hydrogen atoms, and R 1 , R 2 , R 3 and R 4 have the abovementioned meaning can be prepared according to the route described in Scheme 2.
  • a compound of general formula (IX) wherein R 2 has the abovementioned meaning can be obtained from an aldehyde of general formula (VII) and a compound of general formula (VIII) in the presence of a base such as aqueous potassium hydroxide or sodium hydroxide in a solvent such as ethanol (Annan, 1989).
  • the formed 2-oxo-buten-3-oic acid derivative (IX) can be reacted with a compound of general formula R 3 R 4 NH in an inert organic solvent such as dichloromethane in the presence of an activating or coupling reagent such as HBTU to give an amide derivative of general formula (X), wherein R 2 , R 3 and R 4 have the abovementioned meaning.
  • a base such as triethylamine or Hünigs base (DIPEA) may be added in such a reaction.
  • DIPEA triethylamine or Hünigs base
  • a compound of general formula (X) can be reacted with a hydrazine derivative of general formula R 1 NHNH 2 or its hydrate R 1 NHNH 2.
  • a hydrazine of general formula R 1 NHNH 2 (XI) can be prepared from hydrazine or hydrazine hydrate or a salt thereof and a compound of general formula R 1 -L (XII) wherein L is a ‘leaving group’ such as iodide, bromide or chloride in an organic solvent such as ethanol, analogously to the method described ( Chem. Ber. 1965).
  • a hydrazine of general formula R 1 NHNH 2 (XI) or its hydrate R 1 NHNH 2. H 2 O or a salt thereof, wherein R 1 has the above-mentioned meaning, can be prepared from a compound of general formula R 1 -L (XII) in an organic solvent such as acetonitrile, in a reaction with a protected hydrazine derivative such as tert-butylcarbazate to give a compound of general formula (XIII) which compound of general formula (XIII) is subsequently reacted with an acid such as hydrochloric acid in an inert organic solvent such as 1,4-dioxane.
  • an organic solvent such as acetonitrile
  • the invention relates to compounds of the general formula (X):
  • R 2 has the same meaning as given hereinabove
  • R 3 is a hydrogen atom
  • R 4 is chosen from C 6-10 bicycloalkyl and C 7-10 tricycloalkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different and are chosen from methyl, ethyl, hydroxyl, amino, and fluoro or R 4 is chosen from 2-phenyl-1,1-dimethyl-ethyl and 1-phenyl-1-methyl-ethyl, wherein the phenyl groups are optionally substituted with 1-5 substituents Y is as defined above.
  • Such compounds being useful in the synthesis of compounds of the general formula (I) are new.
  • salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid such as fumaric acid.
  • a suitable acid for instance an inorganic acid such as hydrochloric acid, or with an organic acid such as fumaric acid.
  • Intermediate (II-2) was obtained in 94% yield analogously to the preparation of intermediate (II-1) from oxo-acetic acid ethyl ester and 4,4,4-trifluorobutylhydrazine.HCl.H 2 O (Intermediate XI-3) in the presence of 1.2 molar equivalent of Hünig's base (DIPEA).
  • NCS N-chlorosuccinimide
  • Step A To a magnetically stirred solution of tert-butylcarbazate (47.5 gram, 359 mmol) in anhydrous acetonitrile (300 ml) was successively added DIPEA (Hünig's base) (37.6 ml, 216 mmol) and 1-bromobutane (19.3 ml, 180 mmol). The resulting mixture was reacted at 60° C. for 16 hours.
  • DIPEA Heünig's base
  • Step B To a magnetically stirred solution of N′-butylhydrazine-carboxylic acid tert-butyl ester (intermediate XIII-1) (13.17 gram, 70 mmol) in 1,4-dioxane (100 ml) was added excess (12 mol equivalents) hydrochloric acid (12 N) and the resulting mixture was reacted for 16 hours at room temperature. The resulting mixture was concentrated in vacuo and triturated with diethyl ether to give n-butylhydrazine.HCl.H 2 O (Intermediate XI-2) (9.63 gram, 92% yield).
  • Step A Intermediate (XI-3) was obtained analogously to the procedure described for intermediate (XI-2) from tert-butylcarbazate and 1-bromo-4,4,4-trifluorobutane via N′-(4,4,4-trifluorobutyl)hydrazine-carboxylic acid tert-butyl ester (intermediate XIII-2): Intermediate XIII-2: 1 H-NMR (400 MHz, CDCl 3 ) ⁇ 1.46 (s, 9H), 1.67-1.76 (m, 2H), 2.10-2.24 (m, 2H), 2.87-2.94 (m, 2H), 3.97 (br s, 1H), 6.05 (br s, 1H).
  • Step B N′-(4,4,4-trifluorobutyl)hydrazine-carboxylic acid tert-butyl ester (intermediate XIII-2) was converted with excess hydrochloric acid to intermediate (XI-3) (4,4,4-trifluorobutylhydrazine.HCl.H 2 O) analogously as described for the preparation of intermediate XI-2 (part B).
  • Compound 12 was separated by preparative chiral HPLC into 4 separate stereoisomers (compounds 40, 41, 42 and 43, respectively).
  • Racemic compound 22 (1.88 gram) was separated by preparative chiral HPLC into 2 separate enantiomers (compounds 44 and 45, respectively).
  • DAD Diode array detection
  • Compound 103 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamide] (Intermediate X-2) and n-butylhydrazine analogously to the procedure described for compound 101.
  • Compound 104 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamide] (Intermediate X-2) and n-pentylhydrazine (Intermediate XI-1) analogously to the procedure described for compound 101.
  • Compound 106 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [2-(4-fluorophenyl)-2,2-dimethyl-ethyl]amide (Intermediate X-4) and n-pentylhydrazine (Intermediate XI-1) analogously to the procedure described for compound 101.
  • the affinity of the compounds of the invention for cannabinoid CB 1 receptors can be determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabinoid CB 1 receptor is stably transfected in conjunction with [ 3 H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [ 3 H]-ligand, with or without addition of one or more compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
  • CHO Chinese hamster ovary
  • the affinity of the compounds of the invention for cannabinoid CB 2 receptors can be determined using membrane preparations of CHO cells in which the human cannabinoid CB 2 receptor is stably transfected in conjunction with [ 3 H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [ 3 H]-ligand, with or without addition of one or more compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
  • CB 1 receptor antagonism/agonism can be assessed with the human CB 1 receptor cloned in CHO cells.
  • CHO cells are grown in a Dulbecco's Modified Eagle's medium (DMEM) culture medium, supplemented with 10% heat-inactivated fetal calf serum.
  • DMEM Dulbecco's Modified Eagle's medium
  • Medium is aspirated and replaced by DMEM, without fetal calf serum, but containing [ 3 H]-arachidonic acid and incubated overnight in a cell culture stove (5% CO 2 /95% air; 37° C.; water-saturated atmosphere). During this period [ 3 H]-arachidonic acid is incorporated in membrane phospholipids.
  • CB 1 agonist stimulation leads to activation of PLA 2 followed by release of [ 3 H]-arachidonic acid into the medium.
  • This CB 1 agonist-induced release is concentration-dependently antagonized by CB 1 receptor antagonists, such as for example rimonabant.
  • Reference compounds used to assess cannabinoid CB 2 receptor mediated adenylate cyclase activity were the full cannabinoid CB 2 receptor agonists JWH-133 (Huffman, 1999 b ) and WIN 55, 212-2 (Huffman, 1999 a ), and the inverse agonist or antagonist SR-144528 (Rinaldi-Carmona, 1998). Compounds were studied in a concentration range of 10 ⁇ 10 M to 10 ⁇ 6 M. pEC 50 and the pA 2 were calculated according to Cheng-Prusoff equation (Cheng and Prusoff, 1973). Two independent experiments were performed in triplicate.
  • the compounds of the invention have a high affinity for cannabinoid-CB 1 and CB 2 receptors, and are agonists on CB 1 receptors.
  • cannabinoid-CB 1 and CB 2 receptors are agonists on CB 1 receptors.
  • 1,3,5-trisubstituted pyrazoline derivatives described in e.g., WO 2005/074920, WO 2005/077911 and WO 2007/009689 as cannabinoid CB 1 receptor ‘modulating’ agents, a definition embracing agonists, invariably were shown to be antagonists.
  • compounds of formula (I) can be formulated into pharmaceutical compositions that are important and novel embodiments of the invention because they contain the compounds, more particularly specific compounds disclosed herein.
  • Types of pharmaceutical compositions that may be used include, but are not limited to, tablets, chewable tablets, capsules (including microcapsules), solutions, parenteral solutions, ointments (creams and gels), suppositories, suspensions, and other types disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art.
  • the active ingredient for instance, may also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters.
  • compositions are used for oral, intravenous, subcutaneous, tracheal, bronchial, intranasal, pulmonary, transdermal, buccal, rectal, parenteral or other ways to administer.
  • the pharmaceutical formulation contains at least one compound of formula (I) in a mixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.
  • the total amount of active ingredients may be in amounts, for example, from about 0.1% (w/w) to about 95% (w/w) of the formulation, and from 0.5% to 50% (w/w), and further from 1% to 25% (w/w).
  • the compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid, powdered ingredients, such as the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances.
  • auxiliary substances such as liquid or solid, powdered ingredients, such as the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances.
  • auxiliary substances include magnesium carbonate, titanium dioxide, lactose, saccharose, sorbitol, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, amylopectin, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
  • the mixture may then be processed into granules or pressed into tablets.
  • a tablet is prepared using the ingredients below:
  • the components are blended and compressed to form tablets each weighing 230 mg.
  • the active ingredients may be separately premixed with the other non-active ingredients, before being mixed to form a formulation.
  • the active ingredients may also be mixed with each other, before being mixed with the non-active ingredients to form a formulation.
  • Soft gelatin capsules may be prepared with capsules containing a mixture of the active ingredients of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules.
  • Hard gelatin capsules may contain granules of the active ingredients.
  • Hard gelatin capsules may also contain the active ingredients together with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.
  • Dosage units for rectal administration may be prepared (i) in the form of suppositories that contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule that contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
  • Liquid preparations may be prepared in the form of syrups, elixirs, concentrated drops or suspensions, e.g. solutions or suspensions containing the active ingredients and the remainder consisting, for example, of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, preservatives, saccharine and carboxymethyl cellulose or other thickening agents.
  • Liquid preparations may also be prepared in the form of a dry powder, reconstituted with a suitable solvent prior to use. Solutions for parenteral administration may be prepared as a solution of a formulation of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients, preservatives and/or buffering ingredients. Solutions for parenteral administration may also be prepared as a dry preparation, reconstituted with a suitable solvent before use.
  • formulations and ‘kits of parts’ comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention, for use in medical therapy.
  • container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration.
  • formulations of the invention in the manufacture of medicaments for use in the treatment of a condition in which activation of cannabinoid CB 1 receptors is required or desired, and methods of medical treatment or comprising the administration of a therapeutically effective total amount of at least one compound of formula (I), to a patient suffering from, or susceptible to, a condition in which activation of cannabinoid CB 1 receptors is required or desired.
  • compositions comprising exemplary active compounds for systemic use or topical application.
  • Other compounds of the invention or combinations thereof may be used in place of (or in addition to) said compounds.
  • concentration of the active ingredient may be varied over a wide range as discussed herein. Amounts and types of ingredients that may be included are known in the art.

Abstract

The invention is directed to 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor agonists, to pharmaceutical compositions comprising these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, administered to patients to achieve a therapeutic effect in disorders in which CB1 receptors are involved, or that can be treated via manipulation of those receptors.
Compounds of the present invention include compounds of formula (I):
Figure US20110160459A1-20110630-C00001
wherein the substituents have the definitions given in the specification.

Description

  • This application claims the benefit of U.S. provisional application No. 60/973,863, filed Sep. 20, 2007, the disclosure of which is incorporated herein by reference.
  • The present disclosure relates to the fields of pharmaceutical and organic chemistry, and provides 5-(hetero)aryl-4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives, intermediates for synthesizing these compounds, formulations comprising these compounds, and methods of treatment using these compounds.
  • The endogenous cannabinoid receptor agonist, anandamide, is too unstable to be of practical value as a drug. The same is true for other endocannabinoids such as 2-arachidonoyl-glycerol and noladin ether. With the exception of Δ9-tetrahydrocannabinol (Δ9-THC, dronabinol, Marinol®) and Nabilone (Cesamet®) no other cannabinoid receptor agonists have been registered as drugs. In addition, Sativex® (an extract from the Cannabis sativa L. plant) has been recently approved as a prescription medicine (Barnes, 2006). Compounds like CP 55,940 and WIN 55, 212-2 are not registered drugs, but have been, and still are, used as pharmacological tools.
  • It has been postulated that cannabinoid CB1 receptors can occur in two different states: the active ‘R*-state’ to which agonists bind, and the inactive ‘R-state’ to which antagonists or inverse agonists—such as rimonabant—bind. Both states have considerably different three-dimensional geometries. Key interaction in the cannabinoid-CB1 receptor model (based on Palczewski's X-ray structure of bovine rhodopsin) is a hydrogen bond between the carbonyl group of, e.g., the CB1 receptor inverse agonist rimonabant, and the LYS192 residue of the CB1 receptor. This hydrogen bond has a stabilizing effect on the Lys192-Asp366 salt bridge of the intracellular end of the transmembrane helices 3 and 6. The existence of this specific salt bridge is induced by a pronounced kink at Pro 358 in transmembrane helix 6, present in the inactive R-state of the receptor, but not in the active R*-state, which is stabilized by CB1 receptor agonist binding (Hurst, 2002; Shim, 2002; Reggio, 2003; Pertwee, 2005 and Lange, 2005). Thus, it is not possible to apply structural features of known CB1 receptor antagonists or inverse agonists to design novel CB1 receptor agonists in a straightforward manner.
  • Ample evidence exists that cannabinoid receptor agonists have therapeutic possibilities as appetite stimulants, enti-emetics, analgesics, anti-glaucoma agents (Croxford, 2003; Drysdale, 2003), tumor growth inhibitors (Ligresti, 2003), and agents for the treatment of neurodegenerative disorders, including multiple sclerosis and Alzheimer's disease (Smith, 2004; Croxford, 2004).
  • Figure US20110160459A1-20110630-C00002
    Figure US20110160459A1-20110630-C00003
  • Thus, there is a need to develop novel compounds with CB1 receptor agonistic activity, structurally unrelated to known cannabinoid receptor agonists.
    • DISCLOSURE
  • Surprisingly, the inventors found that replacing the 1-aryl or 1-heteroaryl group in 4,5-dihydro-pyrazole CB1 receptor antagonists described in WO 2005/074920, WO 2005/077911 or WO 2007/009689 by an optionally substituted alkyl moiety, resulted in novel compounds with a high affinity for CB1 receptors, wherein these compounds may act as full or partial agonists at CB1 receptors. Moreover, most of these compounds also showed affinity for CB2 receptors.
  • In one embodiment, the invention relates to compounds of formula (I):
  • Figure US20110160459A1-20110630-C00004
  • or tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmaceutically acceptable salts of any of the foregoing,
    wherein:
  • R1 is chosen from:
      • C3-10 linear alkyl, C4-10 branched alkyl, C4-10 alkenyl, C4-10 alkynyl, C3-10-heteroalkyl, C5-8-cycloalkyl-C1-8-alky, and C5-8-heterocycloalkyl-C1-5-alkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino, cyano and fluoro,
      • aryl-C1-3-alkyl, heteroaryl-C1-3-alkyl, aryl-C1-3-heteroalkyl, and heteroaryl-C1-3-heteroalkyl, wherein the aryl and heteroaryl groups are optionally substituted with 1-5 substituents Y, wherein each Y is the same or different, and is chosen from C1-3-alkyl, C1-3-alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (C1-2)-amido, (C1-3)-alkyl sulfonyl, dimethylsulfamido, C1-3-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, phenyl and acetyl, and
      • 2-cyano-ethyl;
  • R2 is chosen from aryl and heteroaryl, each of which may be optionally substituted with 1-5 substituents Y as defined above;
  • R3 is chosen from:
      • linear and branched C3-10 alkyl, C3-8 cycloalkyl, C5-10 bicycloalkyl, C6-10 tricycloalkyl and C8-11 tetracycloalkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino, and fluoro,
      • C3-8 cycloalkyl substituted with aryl and heteroaryl, wherein the aryl and heteroaryl are optionally substituted with 1-5 substituents Y as defined above,
      • 2,2,2-trifluoroethyl and 2-fluoroethyl,
      • C5-8 heterocycloalkyl, C6-10 bicycloheteroalkyl, and C7-10 tricycloheteroalkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino and fluoro,
      • C3-8 C5-10-bicycloalkyl-C1-3-alkyl, and C6-10-tricycloalkyl-C1-3-alkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino and fluoro,
      • branched and linear C3-8 heterocycloalkyl-C1-3-alkyl, C5-10 bicycloheteroalkyl-C1-3-alkyl, and C6-10 tricycloheteroalkyl-C1-3-alkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino and fluoro,
      • aryl and heteroaryl, each of which may be optionally substituted with 1-5 substituents Y as defined above,
      • aryl-C1-5-alkyl, heteroaryl-C1-5-alkyl, and diaryl-C1-5-alkyl, wherein the aryl and heteroaryl groups are optionally substituted with 1-5 substituents Y as defined above,
      • linear and branched C4-8 alkenyl and C4-8 alkynyl, each of which may be optionally substituted with 1-3 fluorine atoms, and
      • branched and linear C2-10 heteroalkyl, comprising 1-2 heteroatoms chosen from N,
  • O, or S;
  • R4 is chosen from hydrogen and C1-4 alkyl;
  • R5 is chosen from hydrogen and C1-2 alkyl, optionally substituted with 1-3 fluorine atoms; and
  • R6 is chosen from hydrogen and C1-2 alkyl, optionally substituted with 1-3 fluorine atoms.
  • In another embodiment, the invention relates to compounds of formula (I):
  • Figure US20110160459A1-20110630-C00005
  • or tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmaceutically acceptable salts of any of the foregoing,
    wherein:
  • R1 is chosen from:
      • C3-10 linear alkyl, C4-10 branched alkyl, and C5-8-cycloalkyl-C1-5-alkyl, each of which may be optionally substituted with 1-3 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, cyano, and fluoro,
      • aryl-C1-3-alkyl, wherein the aryl group is optionally substituted with 1-3 substituents Y, wherein each Y is the same or different, and is chosen from C1-3-alkyl, C1-3-alkoxy, halogen, trifluoromethyl, trifluoro-methoxy, nitro, cyano, and phenyl, and
      • 2-cyano-ethyl;
  • R2 is chosen from phenyl, thienyl, benzothienyl, and pyridyl, each of which may be optionally substituted with 1 or 2 substituents, wherein the substituents are the same or different, and are chosen from halogen, methyl, CF3, OCH3, and OCF3;
  • R3 is chosen from:
      • linear and branched C3-10 alkyl, C3-8 cycloalkyl, C5-10 bicycloalkyl, and C6-10 tricycloalkyl, each of which may be optionally substituted with 1-3 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino, fluoro and aryl,
      • C5-8 heterocycloalkyl optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, and fluoro,
      • C3-8 cycloalkyl-C1-3-alkyl, C5-10-bicycloalkyl-C1-3-alkyl, and C6-10-tricycloalkyl-C1-3-alkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, and fluoro,
      • aryl and heteroaryl, each of which may be optionally substituted with 1-5 substituents Y, wherein each Y is the same or different, and is chosen from C1-3-alkyl, C1-3-alkoxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, cyano, and phenyl,
      • aryl-C1-5-alkyl, heteroaryl-C1-5-alkyl, and diaryl-C1-5-alkyl, wherein the aryl and heteroaryl groups are optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from C1-3-alkyl, C1-3-alkoxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, cyano, and phenyl,
      • branched and linear C2-10 heteroalkyl, comprising 1-2 heteroatoms chosen from N, O, and S; and
  • R4, R5, and R6 are as defined above.
  • In another embodiment, the invention relates to compounds of formula (I):
  • Figure US20110160459A1-20110630-C00006
  • or tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmaceutically acceptable salts of any of the foregoing,
    wherein:
  • R1 is chosen from:
      • C3-8 linear alkyl, C4-8 branched alkyl, and C5-6-cycloalkyl-C1-5-alkyl, each of which may be optionally substituted with 1-3 substituents, wherein the substituents are the same or different, and are chosen from cyano and fluoro,
      • aryl-C1-3-alkyl and 2-cyano-ethyl;
  • R2 is chosen from phenyl, thienyl, benzothienyl, and pyridyl, each of which may be optionally substituted with halogen, methyl, CF3, OCH3, and OCF3; and
  • R3, R4, R5, and R6 are as defined above.
  • In another embodiment, the invention relates to compounds of formula (I):
  • Figure US20110160459A1-20110630-C00007
  • or tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmaceutically acceptable salts of any of the foregoing,
    wherein:
  • R1 is chosen from 2-cyano-ethyl, n-propyl, n-butyl, 4,4,4-trifluorobutyl, isobutyl, n-pentyl, cyclohexylmethyl, and phenethyl;
  • R2 is chosen from 2-fluorophenyl, 3-(trifluoromethyl)phenyl, 3-chlorophenyl, 3-fluorophenyl, 3-methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, benzothien-3-yl, pyrid-2-yl, thien-3-yl, and phenyl;
  • R3 is chosen from 3-(trifluoromethyl)benzyl, 3-(trifluoromethyl)benzyl, 1-(4-fluorophenyl)-1-methyl-ethyl, 1-phenyl-1-methyl-ethyl, 1-phenyl-ethyl, 2-indanyl, 2-(4-fluorophenyl)-1,1-dimethyl-ethyl, 2-(trifluoromethyl)benzyl, 2,2-dimethylpropyl, 2,2-diphenylethyl, 2,2-diphenylpropyl, 2-methoxybenzyl, 2-phenyl-propyl, 2-phenyl-trans-cyclopropyl, 2-trifluoromethyl)phenyl, 3,4,5-trimethoxybenzyl, 3,4-dimethoxybenzyl, 3-fluorobenzyl, 3-methoxybenzyl, 4-chlorobenzyl, 4-methoxybenzyl, 5-methyl-thiazol-2-yl, adamant-1-yl, adamant-2-yl, adamantylmethyl, benzyl, cycloheptyl, cyclohexylmethyl, cyclooctyl, endo-bicyclo[2.2.1]hept-2-yl, exo-bicyclo[2.2.1]hept-2-yl, indan-2-yl, N,2,2,6,6-pentamethylpiperidin-4-yl, naphth-1-yl, naphthalen-1-yl-methyl, noradamant-1-yl, pyridin-3-ylmethyl, quinolin-3-yl, tert-butyl, (1-ethyl)propyl, (1R,2S,5R)-rel-6,6-dimethylbicyclo[3.1.1.]heptan-2-methyl, (3-dimethylamino)-2,2-dimethylpropyl, (furan-2-yl)methyl, (pyridin-3-yl)-methyl, 1-(4-fluorophenyl)-1-methyl-ethyl, 1-(adamant-1-yl)-ethyl, 1-phenyl-1-methyl-ethyl, 2-(4-fluorophenyl)ethyl, 2-(7-methyl-indol-3-yl)ethyl, 2-(indol-3-yl)ethyl, 2-(thien-2-yl)ethyl, 3-(trifluoromethyl)benzyl, 3,3-diphenylpropyl, 3,4-difluorobenzyl, 4-(trifluoromethyl)benzyl, endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl, naphthalen-1-yl-methyl, benzyl, cyclohexylmethyl, cyclopentyl, methyl-N-(Naphthalen-1-yl-methyl), and phenyl;
  • R4 is chosen from hydrogen and methyl;
  • R5 is chosen from hydrogen and methyl; and
  • R6 is hydrogen.
  • In another embodiment, the invention relates to compounds of formula (I):
  • Figure US20110160459A1-20110630-C00008
  • or tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmaceutically acceptable salts of any of the foregoing, wherein the compounds of formula (I) are optically active enantiomers.
  • In a further embodiment, the invention relates to compounds of formula (I):
  • Figure US20110160459A1-20110630-C00009
  • or tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmaceutically acceptable salts of any of the foregoing, having cannabinoid CB1 receptor agonistic activity.
  • In a further embodiment, the invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, for the treatment of disorders in which cannabinoid receptors are involved, and in addition, that can be treated via manipulation of those receptors.
  • In one embodiment, the invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, for the treatment of multiple sclerosis, traumatic brain injury, pain including chronic pain, neuropathic pain, acute pain and inflammatory pain, osteoporosis, appetite disorders, epilepsy, Alzheimer's disease, Tourette's syndrome, cerebral ischaemia and gastrointestinal disorders.
  • Other embodiments of the invention include, but are not limited to:
  • pharmaceutical compositions for treating, for example, at least one disorder or condition that may be treated by activating at least one cannabinoid CB1 receptor, the compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier;
  • methods of treatment of at least one disorder or condition that may be treated by activating at least one cannabinoid CB1 receptor, the methods comprising administering to a mammal in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof;
  • pharmaceutical compositions for treating, for example, at least one disorder or condition chosen multiple sclerosis, traumatic brain injury, pain including chronic pain, neuropathic pain, acute pain and inflammatory pain, osteoporosis, appetite disorders, epilepsy, Alzheimer's disease, Tourette's syndrome, cerebral ischaemia and gastrointestinal disorders;
  • methods of treatment of at least one disorder or condition chosen from the disorders listed herein, the methods comprising administering to a mammal in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof;
  • pharmaceutical compositions for treatment of at least one disorder or condition chosen from the disorders listed herein, the compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier;
  • methods of treatment of at least one disorder or condition that may be treated by activating at least one cannabinoid CB1 receptor, the methods comprising administering to a patient in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof; and
  • methods of antagonizing at least one cannabinoid CB1 receptor, which comprises administering to a subject in need thereof, an effective amount of a compound of formula (I).
  • The invention also provides for the use of at least one compound or salt according to formula (I) for the manufacture of a medicament.
  • The invention further relates to combination therapies wherein at least one compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed. Such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the compounds of the invention.
  • The invention also provides compounds, pharmaceutical compositions, kits and methods for the treatment of a disorder or condition that may be treated by activating at least one cannabinoid CB1 receptor, the method comprising administering to a patient in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • The invention also provides methods of preparing the compounds of the invention and the intermediates used in those methods.
  • Isolation and purification of the compounds and intermediates described herein can be affected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be taken from the preparations and examples. However, other equivalent separation or isolation procedures could, of course, also be used.
  • The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.
  • All compounds of the present invention do contain at least one chiral center (at the 5-position of the 4,5-dihydropyrazole ring). Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention.
  • Cis and trans isomers of the compounds of formula (I) or of pharmaceutically acceptable salts thereof are also within the scope of the invention, and this also applies to tautomers of the compounds of formula (I) or pharmaceutically acceptable salts thereof.
  • Some of the crystalline forms for the compounds may exist as polymorphs, and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
  • Isotopically-labeled compounds of formula (I) or pharmaceutically acceptable salts thereof, including compounds of formula (I) isotopically-labeled to be detectable by PET or SPECT, are also included within the scope of the invention, and the same applies to compounds of formula (I) labeled with [13C]—, [14C]—, [3H]—, [18F]—, [125I]— or other isotopically enriched atoms, suitable for receptor binding or metabolism studies.
  • The compounds of the invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction and disease.
    • DEFINITIONS
  • General terms used in the description of compounds herein disclosed bear their usual meanings. The term alkyl as used herein denotes a univalent saturated branched or straight hydrocarbon chain. Unless otherwise stated, such chains can contain from 1 to 18 carbon atoms. Representative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, and the like. When qualified as ‘lower’, the alkyl group will contain from 1 to 6 carbon atoms. The same carbon content applies to the parent term ‘alkane’, and to derivative terms such as ‘alkoxy’. The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Cx-Cy defines the number of carbon atoms present from the integer “x” to the integer “y” inclusive. ‘Alkyl(C1-3)’ for example, means methyl, ethyl, n-propyl or isopropyl, and ‘alkyl(C1-4)’ means ‘methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl’. The term ‘alkeny’ denotes straight or branched hydrocarbon radicals having one or more carbon-carbon double bonds, such as vinyl, allyl, butenyl, etc., and for example comprises (C2-4) alkenyl. In ‘alkynyl’ groups the straight or branched hydrocarbon radicals have one or more carbon-carbon triple bonds, such as ethynyl, propargyl, 1-butynyl, 2-butynyl, etc., and e.g. includes (C2-4) alkynyl. Unless otherwise stated, alkenyl’ and ‘alkynyl chains can contain from 1 to 18 carbon atoms.
  • The term ‘acyl’ comprises alkyl(C1-3) carbonyl, arylcarbonyl or aryl-alkyl(C1-3)carbonyl. ‘Aryl’ embraces mono- or polycyclic aromatic groups, including phenyl, naphthyl, 1,2,3,4-tetrahydro-naphtyl, indenyl, fluorenyl, anthracenyl, phenanthrenyl, naphthacenyl and azulenyl. ‘Heteroaryl’ embraces mono- or polycyclic hetero-aromatic, including furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, imidazo[2,1-b][1,3]thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, indazolyl, indolyl, indolizinyl, isoindolyl, benzo[b]furanyl, 1,2,3,4-tetrahydroiso-quinolinyl, indanyl, indenyl, benzo[b]thienyl, 2,3-dihydro-1,4-benzodioxin-5-yl, benzimidazolyl, cinnolinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, benzothiazolyl, benzo[1,2,5]thia-diazolyl, purinyl, quinolinyl, isoquinolinyl, quinolizinyl, phtalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl and pteridinyl.
  • ‘Halo’ or ‘Halogen’ means chloro, fluoro, bromo or iodo; ‘hetero’ as in ‘heteroalkyl, heteroaromatic’ etc. means containing one or more N, O or S atoms. ‘heteroalkyl’ includes alkyl groups with heteroatoms in any position, thus including N-bound O-bound or S-bound alkyl groups.
  • The term “substituted” means that the specified group or moiety bears one or more substituents. Where any group may carry multiple substituents, and a variety of possible substituents is provided, the substituents are independently selected, and need not to be the same. The term “unsubstituted” means that the specified group bears no substituents. With reference to substituents, the term “independently” means that when more than one of such substituents are possible, they may be the same or different from each other.
  • ‘C3-8-cycloalky’ means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; ‘C5-8 heterocycloalkyl’ refers to heteroatom containing rings including but not limited to piperidinyl, morpholinyl, azepanyl, pyrrolidinyl, thiomorpholinyl, piperazinyl, tetrahydrofuryl, tetrahydropyranyl; ‘C5-10 bicycloalkyl group’ refers to carbo-bicyclic ring systems including but not limited to bicyclo[2.2.1]heptanyl, bicyclo[3.3.0]octanyl or the bicyclo[3.1.1] heptanyl group; ‘C6-10-tricycloalkyl group’ refers to carbo-tricyclic ring systems including but not limited to the 1-adamantyl, noradamantyl or the 2-adamantyl group. The abbreviation ‘C8-11 tetracycloalkyl group’ refers to carbo-tetracyclic ring systems including but not limited to the cubyl, homocubyl or bishomocubyl group.
  • The terms “oxy”, “thio” and “carbo” as used herein as part of another group respectively refer to an oxygen atom, a sulphur atom and a carbonyl (C═O) group, serving as linker between two groups, such as for instance hydroxyl, oxyalkyl, thioalkyl, carboxyalkyl, etc. The term “amino” as used herein alone, or as part of another group, refers to a nitrogen atom that may be either terminal, or a linker between two other groups, wherein the group may be a primary, secondary or tertiary (two hydrogen atoms bonded to the nitrogen atom, one hydrogen atom bonded to the nitrogen atom and no hydrogen atoms bonded to the nitrogen atom, respectively) amine. The terms “sulfinyl” and “sulfonyl” as used herein as part of another group respectively refer to an —SO— or an —SO2— group.
  • To provide a more concise description, the terms ‘compound’ or ‘compounds’ include tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmacologically acceptable salts, also when not explicitly mentioned.
  • As used herein, the term “leaving group” (L) shall mean a charged or uncharged atom or group that departs during a substitution or displacement reaction. The term refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art (Smith, 2001). Examples include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides (Br, Cl, I), triflates, mesylates, tosylates, and the like.
  • N-oxides of the compounds mentioned above belong to the invention. Tertiary amines may or may not give rise to N-oxide metabolites. The extent to what N-oxidation takes place varies from trace amounts to a near quantitative conversion. N-oxides may be more active than their corresponding tertiary amines, or less active. Whilst N-oxides can easily be reduced to their corresponding tertiary amines by chemical means, in the human body this happens to varying degrees. Some N-oxides undergo nearly quantitative reductive conversion to the corresponding tertiary amines, in other cases conversion is a mere trace reaction, or even completely absent (Bickel, 1969).
  • ‘Form’ is a term encompassing all solids: polymorphs, solvates, amorphous forms. ‘Crystal form’ refers to various solid forms of the same compound, for example polymorphs, solvates and amorphous forms. ‘Cocrystals’ are multicomponent crystals with a unique lattice: new chemical species produced with neutral compounds. ‘Amorphous forms’ are non-crystalline materials with no long range order, and generally do not give a distinctive powder X-ray diffraction pattern. Crystal forms in general have been described by Byrn (1995) and Martin (1995). ‘Polymorphs’ are crystal structures in which a compound can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Polymorphism is a frequently occurring phenomenon, affected by several crystallization conditions such as temperature, level of supersaturation, the presence of impurities, polarity of solvent, rate of cooling. Different polymorphs usually have different X-ray diffraction patterns, solid state NMR spectra, infrared or Raman spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate.
  • To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about”. It is understood that whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to the experimental and/or measurement conditions for such given value.
  • Throughout the description and the claims of this specification the word “comprise” and variations of the word, such as “comprising” and “comprises” is not intended to exclude other additives, components, integers or steps.
  • While it may be possible for the compounds of formula (I) to be administered as the raw chemical, in at least one embodiment, they are presented in a ‘pharmaceutical composition’. According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers thereof, and optionally one or more other therapeutic ingredients. The carrier(s) must be ‘acceptable’ in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • The term “composition” as used herein encompasses a product comprising specified ingredients in predetermined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts. In relation to pharmaceutical compositions, this term encompasses a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. In general, pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. The pharmaceutical composition includes enough of the active object compound to produce the desired effect upon the progress or condition of diseases. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Within the context of this application, the term ‘combination preparation’ comprises both true combinations, meaning a compound of formula (I) and other medicaments physically combined in one preparation such as a tablet or injection fluid, as well as ‘kit-of-parts’, comprising a compound of formula (I) and another medicament in separate dosage forms, together with instructions for use, optionally with further means for facilitating compliance with the administration of the component compounds, e.g., label or drawings. With true combinations, the pharmacotherapy by definition is simultaneous. The contents of ‘kit-of-parts’, can be administered either simultaneously or at different time intervals. Therapy being either concomitant or sequential will be dependant on the characteristics of the other medicaments used, characteristics like onset and duration of action, plasma levels, clearance, etc., as well as on the disease, its stage, and characteristics of the individual patient.
  • The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined as described below. From the binding affinity measured for a given compound of formula (I), one can estimate a theoretical lowest effective dose. At a concentration of the compound equal to twice the measured Ki-value, nearly 100% of the cannabinoid CB1 receptors likely will be occupied by the compound. Converting that concentration to mg of compound per kg of patient—assuming ideal bioavailability—results in a theoretical lowest effective dose. Pharmacokinetic, pharmacodynamic, and other considerations may alter the dose actually administered to a higher or lower value. The dose of the compound to be administered will depend on the relevant indication, the age, weight and sex of the patient and may be determined by a physician. In general, the dosage may be in amounts, for example from 0.01 mg/kg to 10 mg/kg. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician. In general, total daily dose administration to a patient in single or individual doses, may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily, and more usually from 0.01 to 1,000 mg per day, of total active ingredients. Such dosages will be administered to a patient in need of treatment from one to three times each day, or as often as needed for efficacy, and for periods of at least two months, more typically for at least six months, or chronically.
  • The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent to treat a condition treatable by administrating a composition of the invention. That amount is the amount sufficient to exhibit a detectable therapeutic or ameliorative response in a tissue system, animal or human. The effect may include, for example, treating the conditions listed herein. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician (researcher, veterinarian, medical doctor or other clinician), and the therapeutics, or combination of therapeutics, selected for administration. Thus, it is not useful to specify an exact effective amount in advance.
  • A “pharmaceutical salt” refers to an acid:base complex containing an active pharmaceutical ingredient (API) along with additional non-toxic molecular species in the same crystal structure. The term “pharmaceutically acceptable salt” refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. They can be prepared in situ when finally isolating and purifying the compounds of the invention, or separately by reacting them with pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids (Berge, 1977). Common anions used in pharmaceutically acceptable salts include: chloride, bromide, sulfate, nitrate, phosphate, bicarbonate, mesylate, esylate, isothianate, tosylate, napsylate, besylate, acetate, propionate, maleate, benzoate, salicylate, fumarate, citrate, lactate, maleate, tartrate, pamoate, succinate, glycolate, hexanoate, octanoate, decanoate, stearate, oleate, aspartate and glutamate. Common cations used as counterions in pharmaceutically acceptable salts include: sodium, potassium, calcium, magnesium, lithium, zinc, aluminum, arginine, lysine, histidine, triethylamine, ethanolamine, triethanolamine, ethilenediamine, meglumine, procaine and benzathine.
  • The ‘free base’ form may be regenerated by contacting the salt with a base or acid, and isolating the parent compound in the conventional matter. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • The term “treatment” as used herein refers to any treatment of a mammalian, for example human condition or disease, and includes: (1) inhibiting the disease or condition, i.e., arresting its development, (2) relieving the disease or condition, i.e., causing the condition to regress, or (3) stopping the symptoms of the disease. The term ‘inhibit’ includes its generally accepted meaning which includes restraining, alleviating, ameliorating, and slowing, stopping or reversing progression, severity, or a resultant symptom. As used herein, the term “medical therapy” intends to include diagnostic and therapeutic regimens carried out in vivo or ex vivo on humans or other mammals. ‘Mammals’ include animals of economic importance such as bovine, ovine, and porcine animals, especially those that produce meat, as well as domestic animals, sports animals, zoo animals, and in at least one embodiment humans. The term “subject” as used herein, refers to an animal, in at least one embodiment, a mammal, for example a human, who has been the object of treatment, observation or experiment.
    • EXAMPLES Example 1 Materials and Methods
  • 1H NMR spectra were recorded on a Varian UN400 instrument (400 MHz) using DMSO-d6 or CDCl3 as solvents with tetramethylsilane as an internal standard. Chemical shifts are given in ppm (δ scale) downfield from tetramethylsilane. Coupling constants (J) are expressed in Hz. Flash chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Column chromatography was performed using silica gel 60 (0.063-0.200 mm, Merck). Sepacore chromatographic separations were carried out using Supelco equipment, VersaFLASH™ columns, VersaPak™ silica cartridges, Büchi UV monitor C-630, Büchi Pump module C-605, Büchi fraction collector C-660 and Büchi pump manager C-615. Melting points were recorded on a Buchi B-545 melting point apparatus or determined by DSC (differential scanning calorimetry) methods. Optical rotations ([α]D) were measured on an Optical Activity polarimeter. Specific rotations are given as deg/dm, the concentration values are reported as g/100 mL of the specified solvent and were recorded at 23° C., unless indicated otherwise.
    • Example 2 General Aspects of Syntheses
  • Pyrazoline derivatives can be obtained by published methods (Bach, 1994). The synthesis of compounds having formula (I) is outlined in Scheme 1. Additional information on activating and coupling methods of amines to carboxylic acids can be found in the literature (Bodanszky, 1994; Akaji, 1994; Albericio, 1997; Montalbetti, 2005).
  • Figure US20110160459A1-20110630-C00010
  • A hydrazone derivative of general formula (II) wherein R1 has the abovementioned meaning and R7 is a C1-3 alkyl group, such as an ethyl group, can be obtained from a compound of general formula R1NHNH2 and ethylglyoxalate. A hydrazone derivative of general formula (II) can be reacted with a chlorinating agent such as tert-butyl hypochlorite or N-chlorosuccinimide (NCS) in an inert solvent to give a compound of general formula (III). A compound of general formula (III) wherein R1 has the abovementioned meaning, and R7 is a C1-3 alkyl group can be reacted with a compound of general formula (IV), wherein R2, R5 and R6 have the above-mentioned meaning, to give a compound of general formula (V) wherein R1, R2, R5, R6 and R7 have the abovementioned meaning. A compound of general formula (V) can be reacted with a base such as aqueous potassium hydroxide or lithium hydroxide to give a carboxylic acid derivative of general formula (VI), or a sodium, potassium, lithium or cesium salt thereof, wherein R1, R2, R5 and R6 have the abovementioned meaning. A compound of general formula (VI) can be reacted with an amine of general formula R3R4NH, wherein R3 and R4 have the abovementioned meaning, in the presence of an activating or coupling reagent such as 2-chloro-1,3-dimethylimidazolinium hexafluorophosphate (CIP), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) or O-benzotriazol-1-yl-N,N,N′,N′-tetramethyl-uronium hexafluorophosphate (HBTU) in an inert organic solvent such as dichloromethane to give a compound of general formula (I) wherein R1, R2, R3, R4, R5 and R6 have the abovementioned meaning. In one embodiment, a base such as triethylamine or Hünigs base (DIPEA) may be added in such reactions.
  • Alternatively, an ester derivative having formula (V) can be reacted in a so-called Weinreb amidation reaction with an amine of general formula R3R4NH to give a compound of general formula (I). Such Weinreb amidation reactions can be promoted by the use of trimethylaluminum Al(CH3)3 (For more information on aluminum-mediated conversion of esters to amides, see Levin, 1982).
  • Another alternative is to chlorinate a carboxylic acid derivative having formula (VI) to the corresponding acid chloride (Va) wherein R8 is a chloro atom using a chlorinating agent such as thionyl chloride (SOCl2) or oxalyl chloride. The formed acid chloride derivative can subsequently be reacted with an amine of general formula R3R4NH to give a compound of general formula (I), wherein R1, R2, R3, R4, R5 and R6 have the abovementioned meaning.
  • In one embodiment, the invention relates to compounds of formula (Va):
  • Figure US20110160459A1-20110630-C00011
  • or tautomers, stereoisomers, N-oxides, isotopically-labelled analogues, or pharmacologically acceptable salts of any of the foregoing,
    wherein R1, R2, R5 and R6 have the abovementioned meaning and R8 is chosen from chloro and OR7, where R7 is C1-3 alkyl, provided that if R2 is phenyl and R1 is benzyl, then R7 is not ethyl. Such compounds are useful in the synthesis of compounds of the general formula (I).
  • In another embodiment, the invention relates to compounds of formula (VI):
  • Figure US20110160459A1-20110630-C00012
  • and to sodium, potassium, lithium and cesium salts thereof,
    wherein:
    R1, R2, R5 and R6 have the same meanings as given above, provided that if R2 is phenyl, then R1 is not benzyl. Such compounds are useful in the synthesis of compounds of the general formula (I).
  • Figure US20110160459A1-20110630-C00013
  • Alternatively, a compound of general formula (I) wherein R5 and R6 are hydrogen atoms, and R1, R2, R3 and R4 have the abovementioned meaning can be prepared according to the route described in Scheme 2. A compound of general formula (IX) wherein R2 has the abovementioned meaning can be obtained from an aldehyde of general formula (VII) and a compound of general formula (VIII) in the presence of a base such as aqueous potassium hydroxide or sodium hydroxide in a solvent such as ethanol (Annan, 1989). The formed 2-oxo-buten-3-oic acid derivative (IX) can be reacted with a compound of general formula R3R4NH in an inert organic solvent such as dichloromethane in the presence of an activating or coupling reagent such as HBTU to give an amide derivative of general formula (X), wherein R2, R3 and R4 have the abovementioned meaning. In one embodiment, a base such as triethylamine or Hünigs base (DIPEA) may be added in such a reaction. A compound of general formula (X) can be reacted with a hydrazine derivative of general formula R1NHNH2 or its hydrate R1NHNH2.H2O or a salt thereof, wherein R1 has the abovementioned meaning, to give a compound of general formula (I) wherein R1, R2, R3 and R4 have the above-mentioned meaning, and R5 and R6 are hydrogen atoms. A hydrazine of general formula R1NHNH2 (XI) can be prepared from hydrazine or hydrazine hydrate or a salt thereof and a compound of general formula R1-L (XII) wherein L is a ‘leaving group’ such as iodide, bromide or chloride in an organic solvent such as ethanol, analogously to the method described (Chem. Ber. 1965). Alternatively, a hydrazine of general formula R1NHNH2 (XI) or its hydrate R1NHNH2.H2O or a salt thereof, wherein R1 has the above-mentioned meaning, can be prepared from a compound of general formula R1-L (XII) in an organic solvent such as acetonitrile, in a reaction with a protected hydrazine derivative such as tert-butylcarbazate to give a compound of general formula (XIII) which compound of general formula (XIII) is subsequently reacted with an acid such as hydrochloric acid in an inert organic solvent such as 1,4-dioxane.
  • In one embodiment, the invention relates to compounds of the general formula (X):
  • Figure US20110160459A1-20110630-C00014
  • wherein R2 has the same meaning as given hereinabove, R3 is a hydrogen atom, and R4 is chosen from C6-10 bicycloalkyl and C7-10 tricycloalkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different and are chosen from methyl, ethyl, hydroxyl, amino, and fluoro or R4 is chosen from 2-phenyl-1,1-dimethyl-ethyl and 1-phenyl-1-methyl-ethyl, wherein the phenyl groups are optionally substituted with 1-5 substituents Y is as defined above. Such compounds being useful in the synthesis of compounds of the general formula (I) are new.
  • The selection of the particular synthetic procedures depends on factors known to those skilled in the art such as the compatibility of functional groups with the reagents used, the possibility to use protecting groups, catalysts, activating and coupling reagents and the ultimate structural features present in the final compound being prepared.
  • Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid such as hydrochloric acid, or with an organic acid such as fumaric acid.
  • According to these procedures the compounds described below have been prepared. They are intended to further illustrate the invention in more detail, and therefore are not deemed to restrict the scope of the invention in any way. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is thus intended that the specification and examples be considered as exemplary only.
    • Example 3 Synthesis and Spectral Data of Intermediates Intermediate II-1
  • Figure US20110160459A1-20110630-C00015
  • To a magnetically stirred solution of oxo-acetic acid ethyl ester (35.08 ml, 177 mmol; 50% solution in toluene) in ethanol (450 ml) was added n-pentylhydrazine (21.7 g, 212 mmol) and the resulting solution was heated at 80° C. for 16 hours. The obtained mixture was allowed to attain room temperature and concentrated. The resulting residue was taken up in ethylacetate and water. The organic layer was separated and subsequently dried over MgSO4, filtered and concentrated to give (pentylhydrazono)acetic acid ethyl ester (Intermediate II-1) (32.2 gram, 93% yield) as a purple colored oil. 1H-NMR (400 MHz, CDCl3) δ 0.87-0.94 (m, 3H), 1.25-1.42 (m, 7H), 1.55-1.68 (m, 2H), 3.17-3.23 (m, 1H), 3.35-3.45 (m, 1H), 4.28 (q, J=7, 2H), 6.51 (br s, 1H), 6.72 (s, 1H).
    • Intermediate II-2
  • Figure US20110160459A1-20110630-C00016
  • Intermediate (II-2) was obtained in 94% yield analogously to the preparation of intermediate (II-1) from oxo-acetic acid ethyl ester and 4,4,4-trifluorobutylhydrazine.HCl.H2O (Intermediate XI-3) in the presence of 1.2 molar equivalent of Hünig's base (DIPEA). 1H-NMR (400 MHz, CDCl3) δ 1.33 (t, J=7.1 Hz, 3H), 1.84-1.97 (m, 2H), 2.11-2.27 (m, 2H), 3.33-3.40 (m, 2H), 4.28 (q, J=7.2 Hz, 2H), 6.50 (br s, 1H), 6.80 (s, 1H).
    • Intermediate V-1
  • Figure US20110160459A1-20110630-C00017
  • To a magnetically stirred solution of (pentylhydrazono)acetic acid ethyl ester (Intermediate II-1) (35.16 g, 179 mmol) in ethylacetate (450 ml) was added N-chlorosuccinimide (NCS) (26.34 g, 197 mmol) and the resulting mixture was heated at 60° C. for 1 hour in a nitrogen atmosphere. To the reaction mixture was added styrene (41.1 ml, 359 mmol) and potassium bicarbonate (89.8 g, 897 mmol) and water (8 ml). The resulting mixture was heated at 70° C. for 16 hours. The resulting mixture was allowed to attain room temperature, concentrated in vacuo and the resulting residue was chromatographically separated using Sepacore equipment (eluant: dichloromethane/methanol=98/2 v/v) to give ethyl 1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxylate (Intermediate (V-1) (12.1 g, 22% yield) as an oil. 1H-NMR (400 MHz, CDCl3) δ 0.83 (t, J=7, 3H), 1.13-1.28 (m, 4H), 1.35 (t, J=7, 3H), 1.53-1.67 (m, 2H), 2.89 (dd, J=16 and 13, 1H), 3.01-3.09 (m, 1H), 3.14-3.22 (m, 1H), 3.41 (dd, J=16 and 12, 1H), 4.31 (double (diastereotopic) quartet, J˜7, 2H), 4.63 (dd, J=13 and 12, 1H), 7.27-7.39 (m, 5H).
    • Intermediate V-2
  • Figure US20110160459A1-20110630-C00018
  • Intermediate (V-2) was obtained analogously to the preparation of intermediate (V-1) from (butylhydrazono)acetic acid ethyl ester via successive chlorination with N-chlorosuccinimide (NCS) and treatment with trans-beta-methylstyrene. Chromatographic purification using Sepacore equipment (eluant: petroleum eter (40-60)/ethylacetate=9/1 v/v)) gave ethyl 1-(n-butyl)-trans-4-methyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxylate (Intermediate (V-2) in 14% yield. 1H-NMR (400 MHz, CDCl3) δ 0.95 (t, J=7, 3H), 1.18-1.43 (m, 8H), 1.49-1.66 (m, 2H), 3.03-3.26 (m, 3H), 4.09 (d, J=12 Hz, 1H), 4.27-4.37 (m, 2H), 7.28-7.40 (m, 5H).
    • Intermediate V-3
  • Figure US20110160459A1-20110630-C00019
  • Intermediate (V-3) was obtained analogously to the preparation of intermediate (V-1) from (4,4,4-trifluorobutylhydrazono)acetic acid ethyl ester (Intermediate II-2) via successive reactions with N-chlorosuccinimide (NCS) and styrene to give crude intermediate (V-3). This crude material was chromatographically purified by using flash chromatography (eluant gradient: petroleum ether (40-60)/ethylacetate=95/5=>petroleum ether (40-60)/ethylacetate=93/7 (v/v)) to give ethyl 1-(4,4,4-trifluorobutyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxylate (Intermediate (V-3) (34% yield). 1H-NMR (400 MHz, CDCl3) δ 1.35 (t, J=7 Hz, 3H), 1.75-2.22 (m, 4H), 2.93 (dd, J=18 and 14 Hz, 1H), 3.06-3.21 (m, 2H), 3.41 (dd, J=18 and 12 Hz, 1H), 4.33 (double (diastereotopic) quartet, J˜7, 2H), 4.55 (dd, J=14 and 12 Hz, 1H), 7.31-7.42 (m, 5H).
    • Intermediate VI-1
  • Figure US20110160459A1-20110630-C00020
  • To a magnetically stirred solution of ethyl 1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxylate (Intermediate (V-1) (11.76 g, 38.74 mmol) in tetrahydrofuran (100 ml) and water (100 ml) was added lithium hydroxide (1.86 g, 77.5 mmol) and the resulting mixture was heated at 70° C. for 1 hour. The reaction mixture was allowed to attain room temperature and diethyl ether (200 ml) and concentrated hydrochloric acid (7 ml) were added. The organic layer was separated, washed three times with water and with brine and subsequently dried over Na2SO4, filtered and concentrated in vacuo to give 1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxylic acid (Intermediate (VI-1) (7.9 g, 74% yield) as an oil. 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=7, 3H), 1.15-1.28 (m, 4H), 1.53-1.65 (m, 2H), 2.92 (dd, J=17 and 13, 1H), 3.02-3.11 (m, 1H), 3.18-3.27 (m, 1H), 3.44 (dd, J=17 and 13, 1 H), 4.75 t, J=13, 1H), 7.31-7.41 (m, 5H), 7.42-9.00 (br s, 1H).
    • Intermediate IX-1
  • Figure US20110160459A1-20110630-C00021
  • To a magnetically stirred solution of ethyl 2-fluorobenzaldehyde (11.7 ml, 110 mmol) and ethylglyoxalate (11.1 ml, 100 mmol) in ethanol (50 ml) was slowly added a solution of sodium hydroxide (4.4 g (110 mmol) in 50 ml water) in a nitrogen atmosphere while the temperature was kept between 0° C. and 10° C. After stirring for another 45 minutes the reaction mixture was allowed to attain room temperature and stirred for 2 hours. The formed precipitate was collected by filtration and successively washed with ethanol and a 1N HCl solution (200 ml) and subsequently dried to give E-2-oxo-4-(2-fluorophenyl)-but-3-enoic acid (11.1 gram, 57% yield). Melting point: 100-102.5° C. 1H-NMR (400 MHz, CDCl3) δ 7.13-7.27 (m, 2H), 7.45-7.53 (m, 1H) 7.66-7.74 (m, 2H), 8.26 (d, J=16, 1 H), invisible —OH proton.
    • Intermediate X-1
  • Figure US20110160459A1-20110630-C00022
  • To a magnetically stirred solution of the commercially available E-2-oxo-4-phenyl-but-3-enoic acid (4.40 gram, 25 mmol) in dichloromethane (100 ml) was successively added 1-(4-fluorophenyl)-1-methyl-ethylamine (3.83 g, 25 mmol), N-ethyldiisopropylamine (DIPEA) (8.56 ml, 50 mmol) and O-benzotriazol-1-yl-N,N,N′,N′tetramethyluronium hexafluorophosphate (HBTU) (9.48 gram, 25 mmol) and the resulting mixture was reacted at room temperature for 16 hours in a nitrogen atmosphere. The organic layer was washed twice with water and subsequently dried over MgSO4, filtered and concentrated in vacuo to give crude E-2-oxo-4-phenyl-but-3-enoic acid [1-(4-fluorophenyl)-1-methyl-ethyl]amide (Intermediate X-I) as an oil. Further chromatographic purification using Sepacore equipment (eluant: petroleum ether/ethylacetate=95/5 (v/v)) gave intermediate X-I as an oil which slowly solidified on standing (5.15 g, 65% yield). 1H-NMR (400 MHz, CDCl3) δ 1.77 (s, 6H), 7.00-7.05 (m, 2H), 7.35-7.45 (m, 5H), 7.52 (br s, 1H), 7.61-7.65 (m, 2H), 7.73 (d, J=16, 1H), 7.92 (d, J=16, 1H).
    • Intermediate X-2
  • Figure US20110160459A1-20110630-C00023
  • Intermediate X-2 (E-2-oxo-4-phenyl-but-3-enoic acid [endo-(1R,2S,4R)-1,7,7-trimethylbicyclo-[2.2.1]hept-2-ylamide]) was obtained from E-2-oxo-4-phenyl-but-3-enoic acid and endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamine (CAS 32511-34-5) analogously to the procedure described for intermediate X-1. 1H-NMR (400 MHz, CDCl3) δ 0.84-1.00 (m, 10H), 1.21-1.29 (m, 1H), 1.38-1.48 (m, 1H), 1.53-1.62 (m, 1H), 1.70-1.86 (m, 2H), 2.33-2.44 (m, 1H), 4.22-4.30 (m, 1H), 7.20-7.26 (m, 1H), 7.39-7.46 (m, 3H), 7.65-7.70 (m, 2H), 7.78 (d, J=16, 1H), 7.95 (d, J=16, 1H).
    • Intermediate X-3
  • Figure US20110160459A1-20110630-C00024
  • Intermediate X-3 (E-2-oxo-4-(2-fluorophenyl)-but-3-enoic acid [endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamide]) was obtained from E-2-oxo-4-(2-fluorophenyl)-but-3-enoic acid (Intermediate IX-1) and endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamine analogously to the procedure described for intermediate X-1. 1H-NMR (400 MHz, CDCl3) δ 0.84-1.00 (m, 10H), 1.21-1.30 (m, 1H), 1.38-1.48 (m, 1H), 1.53-1.62 (m, 1H), 1.70-1.87 (m, 2H), 2.34-2.44 (m, 1H), 4.21-4.30 (m, 1H), 7.10-7.25 (m, 3H), 7.38-7.45 (m, 1H), 7.70-7.75 (m, 1H), 7.85 (d, J=16, 1H), 8.12 (d, J=16, 1H).
    • Intermediate X-4
  • Figure US20110160459A1-20110630-C00025
  • Intermediate X-4 (E-2-oxo-4-phenyl-but-3-enoic acid [2-(4-fluorophenyl)-2,2-dimethyl-ethyl]amide was obtained from E-2-oxo-4-phenyl-but-3-enoic acid and 2-(4-fluorophenyl)-2,2-dimethyl-ethylamine analogously to the procedure described for intermediate X-1. 1H-NMR (400 MHz, CDCl3) δ 1.40 (s, 6H), 3.08 (s, 2H), 6.91-6.99 (m, 3H), 7.06-7.11 (m, 2H), 7.38-7.47 (m, 3H), 7.65-7.70 (m, 2H), 7.82 (d, J=16, 1H), 7.92 (d, J=16, 1H).
    • Intermediate X-5
  • Figure US20110160459A1-20110630-C00026
  • Intermediate X-5 (E-2-oxo-4-(4-chlorophenyl)-but-3-enoic acid [1-phenyl-1-methyl-ethyl]amide was obtained from E-2-oxo-4-(4-chlorophenyl)-but-3-enoic acid and 1-phenyl-1-methyl-ethylamine analogously to the procedure described for intermediate X-1. 1H-NMR (400 MHz, CDCl3) δ 1.79 (s, 6H), 7.23-7.28 (m, 1H), 7.32-7.43 (m, 6H), 7.51-7.57 (m, 3H), 7.71 (d, J=16 Hz, 1H), 7.85 (d, J=16 Hz, 1H).
    • Intermediate X-6
  • Figure US20110160459A1-20110630-C00027
  • Intermediate X-6 (E-2-oxo-4-(3-methoxyphenyl)-but-3-enoic acid [1-(4-fluorophenyl)-1-methyl-ethyl]amide was obtained from E-2-oxo-4-(3-methoxyphenyl)-but-3-enoic acid and 1-(4-fluorophenyl)-1-methyl-ethylamine analogously to the procedure described for intermediate X-1. 1H-NMR (400 MHz, CDCl3) δ 1.77 (s, 6H), 3.81 (s, 3H), 6.95-7.05 (m, 3H), 7.13-7.16 (m, 1H), 7.18-7.22 (m, 1H), 7.28-7.33 (m, 1H), 7.36-7.40 (m, 2H), 7.54 (br s, 1H), 7.71 (d, J=16 Hz, 1H), 7.88 (d, J=16 Hz, 1H).
    • Intermediate XI-1
  • Figure US20110160459A1-20110630-C00028
  • To a magnetically stirred solution of hydrazine hydrate (243 ml, 5 mol) was very slowly added a solution of 1-bromopentane (62 ml, 0.50 mol) in ethanol (50 ml) while keeping the temperature at 20° C. The resulting mixture was reacted at room temperature for 2 hours. The mixture was extracted with diethyl ether. The diethyl ether extract was concentrated and BaO (5 gram) was added to the residue. Distillation in vacuo gave n-pentylhydrazine (Intermediate XI-1) at 30-40 mbar pressure at 72° C.-78° C. (30.36 gram, 48% yield). 1H-NMR (400 MHz, CDCl3) δ 0.90 (t, J=7, 3H), 1.27-1.38 (m, 4H), 1.45-1.58 (m, 2H), 2.76 (t, J=7, 2H), 2.85 (br s, 3H).
    • Intermediate XI-2
  • Figure US20110160459A1-20110630-C00029
  • Step A: To a magnetically stirred solution of tert-butylcarbazate (47.5 gram, 359 mmol) in anhydrous acetonitrile (300 ml) was successively added DIPEA (Hünig's base) (37.6 ml, 216 mmol) and 1-bromobutane (19.3 ml, 180 mmol). The resulting mixture was reacted at 60° C. for 16 hours. The resulting mixture was allowed to attain room temperature and subsequently concentrated in vacuo and further purified by Sepacore chromatography (eluant: petroleum ether 40-60/ethylacetate=4/1 (v/v)) to give N′-butylhydrazine-carboxylic acid tert-butyl ester (intermediate XIII-1) (13.2 gram, 39%) as a pale yellow oil: 1H-NMR (400 MHz, CDCl3) δ 0.91 (t, J=7, 3H), 1.30-1.49 (m, 13H), 2.81-2.87 (m, 2H), 4.00 (br s, 1H), 6.20 (br s, 1H).
  • Figure US20110160459A1-20110630-C00030
  • Step B: To a magnetically stirred solution of N′-butylhydrazine-carboxylic acid tert-butyl ester (intermediate XIII-1) (13.17 gram, 70 mmol) in 1,4-dioxane (100 ml) was added excess (12 mol equivalents) hydrochloric acid (12 N) and the resulting mixture was reacted for 16 hours at room temperature. The resulting mixture was concentrated in vacuo and triturated with diethyl ether to give n-butylhydrazine.HCl.H2O (Intermediate XI-2) (9.63 gram, 92% yield). 1H-NMR (400 MHz, DMSO-d6/CDCl3=4/1 (v/v)) δ 0.93 (t, J=7, 3H), 1.32-1.43 (m, 2H), 1.56-1.65 (m, 2H), 2.92-2.98 (m, 2H), 7.20 (br s, 6H).
    • Intermediate XI-3
  • Figure US20110160459A1-20110630-C00031
  • Step A: Intermediate (XI-3) was obtained analogously to the procedure described for intermediate (XI-2) from tert-butylcarbazate and 1-bromo-4,4,4-trifluorobutane via N′-(4,4,4-trifluorobutyl)hydrazine-carboxylic acid tert-butyl ester (intermediate XIII-2): Intermediate XIII-2: 1H-NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 1.67-1.76 (m, 2H), 2.10-2.24 (m, 2H), 2.87-2.94 (m, 2H), 3.97 (br s, 1H), 6.05 (br s, 1H).
  • Figure US20110160459A1-20110630-C00032
  • Step B: N′-(4,4,4-trifluorobutyl)hydrazine-carboxylic acid tert-butyl ester (intermediate XIII-2) was converted with excess hydrochloric acid to intermediate (XI-3) (4,4,4-trifluorobutylhydrazine.HCl.H2O) analogously as described for the preparation of intermediate XI-2 (part B). Intermediate (XI-3): 1H-NMR (400 MHz, DMSO-d6 δ1.77 (quintet, J=7.7 Hz, 2H), 2.28-2.43 (m, 2H), 2.94 (t, J=7.4 Hz, 2H), 7.95 (br s, ˜0.3H).
    • Example 4 Synthesis of Specific Compounds
  • Compound 1
  • Figure US20110160459A1-20110630-C00033
    • N-(Adamant-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • To a magnetically stirred solution of 1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxylic acid (Intermediate (VI-1) (0.70 g, 2.55 mmol) in dichloromethane (40 ml) was successively added 2-adamantanamine.HCl (480 mg, 2.55 mmol), N-ethyldiisopropylamine (DIPEA) (1.78 ml, 10.22 mmol) and 2-chloro-1,3-dimethylimidazolinium hexafluorophosphate (CIP) (853 mg, 3.07 mol) and the resulting mixture was reacted at room temperature for 16 hours in a nitrogen atmosphere. The reaction mixture was successively washed twice with water, twice with aqueous citric acid (0.5 M), twice with NaHCO3 (5% aqueous solution) and brine, and subsequently dried over Na2SO4, filtered and concentrated in vacuo to give crude N-(adamant-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (1.26 g) as an orange oil. Further chromatographic purification using Sepacore equipment (eluant: petroleum ether/diethyl ether=85/15 (v/v)) gave compound 1 (750 mg, 67% yield) as an oil. 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7, 3H), 1.21-1.30 (m, 4H), 1.55-1.65 (m, 2H), 1.65-1.70 (m, 2H), 1.76 (br s, 2H), 1.75-1.92 (m, 8H), 1.97-2.01 (m, 2H), 2.82 (dd, J=17 and 14, 1H), 2.92-2.97 (m, 2H), 3.42 (dd, J=17 and 11, 1H), 4.09-4.14 (m, 1H), 4.40 (dd, J=14 and 11, 1H), 6.99-7.07 (m, 1H), 7.28-7.38 (m, 5H).
  • Compounds 2-100 were analogously prepared.
  • Compound 2
  • Figure US20110160459A1-20110630-C00034
    • N-Phenyl-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.87 (t, J=7 Hz, 3H), 1.17-1.34 (m, 4H), 1.55-1.73 (m, 2H), 2.85-3.08 (m, 3H), 3.49 (dd, J=17 and 11.4 Hz, 1H), 4.53 (dd, J=14 and 11.4 Hz, 1H), 7.09 (t, J=7.5 Hz, 1H), 7.28-7.42 (m, 7H), 7.62 (d, J=7.5 Hz, 2H), 8.43 (s, 1H).
  • Compound 3
  • Figure US20110160459A1-20110630-C00035
    • N-(4-Methoxyphenyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=6.9 Hz, 3H), 1.19-1.34 (m, 4H) 1.57-1.69 (m, 2H), 2.85-3.06 (m, 3H), 3.48 (dd, J=17 and 11 Hz, 1H), 3.80 (s, 3H), 4.50 (dd, J=14 and 11.4 Hz, 1H), 6.88 (d, J=9 Hz, 2H), 7.28-7.40 (m, 5H) 7.54 (d, J=9 Hz, 2H), 8.35 (br s, 1H).
  • Compound 4
  • Figure US20110160459A1-20110630-C00036
    • N-(Napht-1-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7 Hz, 3H), 1.20-1.40 (m, 4H), 1.66-1.77 (m, 2H), 2.92-3.14 (m, 3H), 3.55 (dd, J=17 and 11.4 Hz, 1H), 4.59 (dd, J=14 and 11.4 Hz, 1H), 7.30-7.44 (m, 5H), 7.46-7.61 (m, 3H), 7.67 (d, J=8.4 Hz, 1 H), 7.88 (d, J=7.5 Hz, 1H), 7.95 (d, J=8.4 Hz, 1H), 8.20 (d, J=7.5 Hz, 1H), 9.05 (br s, 1H).
  • Compound 5
  • Figure US20110160459A1-20110630-C00037
    • N-(2-Trifluoromethyl)phenyl-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.88 (t, J=7.2 Hz, 3H), 1.18-1.38 (m, 4H), 1.61-1.70 (m, 2H), 2.86-3.11 (m, 3H), 3.49 (dd, J=17 and 11.7 Hz, 1H), 4.59 (dd, J=14 and 11.4 Hz, 1H), 7.17 (t, J=7.7 Hz, 1H), 7.29-7.42 (m, 5H), 7.55 (t, J=7.8 Hz, 1 H), 7.61 (d, J=7.8 Hz, 1H), 8.45 (d, J=8.4 Hz, 1H), 9.05 (br s, 1H).
  • Compound 6
  • Figure US20110160459A1-20110630-C00038
    • N-(Naphthalen-1-ylmethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.79 (t, J=6.9 Hz, 3H), 1.07-1.25 (m, 4H), 1.44-1.58 (m, 2H), 2.78-2.92 (m, 3H), 3.46 (dd, J=17.3, and 11.3 Hz, 1H), 4.41 (dd, J=14.3 and 11.3 Hz, 1H), 5.00 (d, J=5.7 Hz, 2H), 6.90 (br t, J=5.6 Hz, 1H), 7.27-7.37 (m, 5H), 7.42-7.60 (m, 4H), 7.83 (d, J=7.8 Hz, 1H), 7.88 (d, J=1.2 Hz, 1H), 8.10 (d, J=8.1 Hz, 1H).
  • Compound 7
  • Figure US20110160459A1-20110630-C00039
    • N-(Pyridin-3-ylmethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.83 (t, J=6.9 Hz, 3H), 1.14-1.30 (m, 4H), 1.51-1.64 (m, 2H), 2.81-2.99 (m, 3H), 3.44 (dd, J=17.3 and 11.3 Hz, 1H), 4.45 (dd, J=14.30 and 11.29 Hz, 1H), 4.56 (d, J=6.3 Hz, 2H), 7.00 (br t, J=5.9 Hz, 1H), 7.26-7.39 (m, 6H), 7.70 (br d, J=7.8 Hz, 1H), 8.54 (dd, J=4.8 and 1.50 Hz, 1H), 8.60 (d, 1H).
  • Compound 8
  • Figure US20110160459A1-20110630-C00040
    • N-(Cyclohexylmethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 0.90-1.04 (m, 2H), 1.12-1.33 (m, 7H), 1.47-1.82 (m, 8H), 2.76-2.98 (m, 3H), 3.18 (dq, J=12.9 and 6.6 Hz, 2H), 3.41 (dd, J=17.3 and 11 Hz, 1H), 4.39 (dd, J=14.3 and 11 Hz, 1H), 6.68 (br t, J=5.9 Hz, 1H), 7.27-7.41 (m, 5H).
  • Compound 9
  • Figure US20110160459A1-20110630-C00041
    • N-(2,2-diphenylethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.83 (t, J=7.07 Hz, 3H), 1.09-1.28 (m, 4 H), 1.43-1.58 m, 2H), 2.73-2.91 (m, 3H), 3.37 (dd, J=17.2 and 11.1 Hz, 1H), 3.98 (dd, J=7.8 and 6.2 Hz, 2H), 4.26 (t, J=7.8 Hz, 1H), 4.36 (dd, J=14.3 and 11.3 Hz, 1H), 6.62 (br t, J=5.9 Hz, 1H), 7.18-7.37 (m, 15H).
  • Compound 10
  • Figure US20110160459A1-20110630-C00042
    • N-(Benzyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.83 (t, J=6.9 Hz, 3H), 1.13-1.29 (m, 4H), 1.49-1.64 (m, 2H), 2.81-2.96 (m, 3H), 3.44 (dd, J=17.3 and 11.3 Hz, 1H), 4.42 (dd, J=14.5 and 11.1 Hz, 1H), 4.54 (d, J=6 Hz, 2H), 6.94 (br t, J=5.7 Hz, 1H), 7.26-7.40 (m, 10H).
  • Compound 11
  • Figure US20110160459A1-20110630-C00043
    • N-[(1-Ethyl)propyl]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 0.94 (t, J=7, 6 H), 1.17-1.31 (m, 4H), 1.39-1.52 (m, 2H), 1.53-1.69 (m, 4H), 2.78-2.98 (m, 3H), 3.42 (dd, J=17.3 and 11 Hz, 1H), 3.79-3.90 (m, 1H), 4.40 (dd, J=14.4 and 11.1 Hz, 1H), 6.35 (d, J=9.3 Hz, 1H), 7.27-7.40 (m, 5H).
  • Compound 12
  • Figure US20110160459A1-20110630-C00044
    • N-(Exo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (d, J=6.9 Hz, 3H), 1.10-1.65 (m, 13 H), 1.83 (ddd, J=13.1 and 8 and 2.1 Hz, 1H), 2.25-2.34 (m, 2H), 2.76-2.97 (m, 3H), 3.40-3.41 (2×dd, J=18.4 and 11.1 Hz, 1H), 3.79 (br td, J=7.7 and 3.6 Hz, 1H), 4.37-4.38 (2×dd, J=14.4 and 11.1 and 3.3 Hz, 1H), 6.46 (br d, J=7.2 Hz, 1H), 7.27-7.40 (m, 5H).
  • Compound 13
  • Figure US20110160459A1-20110630-C00045
    • N-[2-(4-Fluorophenyl)ethyl]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 1.15-1.31 (m, 4H), 1.51-1.65 (m, 2H), 2.78-2.97 (m, 5H), 3.41 (dd, J=17.1 and 11.1 Hz, 1H), 3.52-3.60 (m, 2H), 4.41 (dd, J=14.3 and 11.3 Hz, 1H), 6.69 (br t, J=5.9 Hz, 1H), 7.00 (br t, J=8.7 Hz, 2H), 7.19 (dd, J=8.4 and 5.4 Hz, 2H), 7.27-7.40 (m, 5H).
  • Compound 14
  • Figure US20110160459A1-20110630-C00046
    • N-(1-Phenyl-ethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (1:1 diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.5 Hz, 3H), 1.15-1.30 (m, 4H), 1.48-1.67 (m, 5H), 2.76-2.96 (m, 3H), 3.39-3.40 (2×dd, J=17.4 and 11.1, 1 H), 4.39-4.40 (2×dd, J=14.3 and 11.1 Hz, 1H), 5.14-5.25 (m, 1H), 6.86 (br d, J=8.1 Hz, 1H), 7.26-7.41 (m, 10H).
  • Compound 15
  • Figure US20110160459A1-20110630-C00047
    • N-(Adamantylmethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 1.18-1.32 (m, 4H), 1.49-1.78 (m, 14H), 2.00 (br s, 3H), 2.78-3.11 (m, 5H), 3.42 (dd, J=17.1 and 11.1 Hz, 1H), 4.40 (dd, J=14.4 and 11.1 Hz, 1H), 6.69 (br t, J=6.3 Hz, 1H), 7.26-7.40 (m, 5H).
  • Compound 16
  • Figure US20110160459A1-20110630-C00048
    • N-[(1-Ethyl)propyl]-1-(n-butyl)-5-(3-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.87 (t, J=7.4 Hz, 3H), 0.94 (t, J=7.4 Hz, 6 H), 1.19-1.70 (m, 8H), 2.79 (dd, J=17.3 and 14.3 Hz, 1H), 2.89-2.95 (m, 2H), 3.43 (dd, J=17.4 and 11.1 Hz, 1H), 3.79-3.90 (m, 1H), 4.36 (dd, J=14.4 and 11.1 Hz, 1H), 6.33 (br d, J=9.3 Hz, 1H), 7.23-7.36 (m, 3H), 7.38 (br s, 1H).
  • Compound 17
  • Figure US20110160459A1-20110630-C00049
    • N-(Cyclooctyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.92 Hz, 3H), 1.16-1.31 (m, 4H), 1.48-1.75 (m, 14H), 1.82-1.94 (m, 2H), 2.76-2.97 (m, 3H), 3.40 (dd, J=17.4 and 11.1 Hz, 1H), 4.00-4.10 (m, 1H), 4.37 (dd, J=14.3 and 11 Hz, 1H), 6.58 (br d, J=8.4 Hz, 1H), 7.27-7.39 (m, 5H).
  • Compound 18
  • Figure US20110160459A1-20110630-C00050
    • N-(2,2-diphenylpropyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7.1 Hz, 3H), 1.10-1.28 (m, 4H), 1.44-1.55 (m, 2H), 1.71 (s, 3H), 2.71-2.87 (m, 3H), 3.37 (dd, J=17.1 and 11.1 Hz, 1 H), 4.02 (d, J=6.3 Hz, 2H), 4.34 (dd, J=14.4 and 11.1 Hz, 1H), 6.41 (br t, J=5.87 Hz, 1 H), 7.19-7.37 (m, 15H).
  • Compound 19
  • Figure US20110160459A1-20110630-C00051
    • N-(Cycloheptyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 1.15-1.31 (m, 4H), 1.45-1.72 (m, 12H), 1.91-2.03 (m, 2H), 2.76-2.97 (m, 3H), 3.40 (dd, J=17.1 and 11.1 Hz, 1H), 3.95-4.08 (m, 1H), 4.38 (dd, J=14.3 and 11 Hz, 1H), 6.57 (br d, J=8.4 Hz, 1H), 7.27-7.40 (m, 5H).
  • Compound 20
  • Figure US20110160459A1-20110630-C00052
    • N-(Quinolin-3-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.88 (t, J=6.92 Hz, 3H), 1.18-1.36 (m, 4H), 1.58-1.71 (m, 2H), 2.91-3.14 (m, 3H), 3.53 (dd, J=17.3 and 11.6 Hz, 1H), 4.62 (dd, J=13.8 and 11.7 Hz, 1H), 7.29-7.45 (m, 5H), 7.53 (br t, J=6.9 Hz, 1H), 7.62 (dt, J=7.7 and 1.50 Hz, 1H), 7.81 (d, J=7.5 Hz, 1H), 8.05 (d, J=8.4 Hz, 1H), 8.69 (s, 1H), 8.83 (d, J=2.4 Hz, 1H), 8.86 (d, J=2.7 Hz, 1H).
  • Compound 21
  • Figure US20110160459A1-20110630-C00053
    • N-(2-phenyl-trans-cyclopropyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.92 Hz, 3H), 1.15-1.33 (m, 6H), 1.52-1.68 (m, 2H), 2.11-2.19 (m, 1H), 2.76-2.98 (m, 4H), 3.41 and 3.43 (2×dd, J=17.2 and 11.2 Hz, 1H), 4.42 (dd, J=14.1 and 11.1 Hz, 1H), 6.84 (br s, 1H), 7.15-7.39 (m, 10H).
  • Compound 22
  • Figure US20110160459A1-20110630-C00054
    • N-[3-(Trifluoromethyl)benzyl)]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.83 (t, J=6.92 Hz, 3H), 1.15-1.30 (m, 4 H), 1.51-1.65 (m, 2H), 2.81-2.99 (m, 3H), 3.45 (dd, J=17.3 and 11.3 Hz, 1H), 4.46 (dd, J=14.4 and 11.4 Hz, 1H), 4.59 (s, 2H), 7.28-7.39 (m, 5H), 7.43-7.50 (m, 1H), 7.52-7.60 (m, 3H).
  • Compound 23
  • Figure US20110160459A1-20110630-C00055
    • N-(2,2-Dimethylpropyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7.22 Hz, 3H), 0.96 (s, 9H), 1.16-1.32 (m, 4H), 1.53-1.67 (m, 2H), 2.77-2.97 (m, 3H), 3.15 (dd, J=6.6 and 1.8 Hz, 2 H), 3.42 (dd, J=17.5 and 11.1 Hz, 1H), 4.41 (dd, J=14.4 and 11.1 Hz, 1H), 6.72 (br t, J=6.2 Hz, 1H), 7.27-7.40 (m, 5H).
  • Compound 24
  • Figure US20110160459A1-20110630-C00056
    • N-(2-Indanyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.82 (t, J=6.9 Hz, 3H), 1.11-1.29 (m, 4H), 1.47-1.64 (m, 2H), 2.77-2.96 (m, 4H), 3.32-3.47 (m, 3H), 4.40 (dd, J=14.3 and 11.3 Hz, 1H), 4.76-4.87 (m, 1H), 6.80 (br d, J=7.8 Hz, 1H), 7.14-7.40 (m, 10H).
  • Compound 25
  • Figure US20110160459A1-20110630-C00057
    • N-[(1R,2S,5R)-rel-6,6-dimethylbicyclo[3.1.1.]heptan-2-methyl]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture) (from (−)-cis-myrtanylamine (CAS 38235-68-6))
  • 1H-NMR (400 MHz, CDCl3) δ 0.80-0.90 (m, 3H), 0.91 (d, J=9.6 Hz, 1H), 1.07 (s, 3H), 1.17-1.32 (m, 7H), 1.47-1.67 (m, 3H), 1.81-2.04 (m, 5H), 2.27-2.42 (m, 2H), 2.77-2.98 (m, 3H), 3.27-3.49 (m, 3H), 4.39 (dd, J=14.4 and 11.1 Hz, 1H), 6.64 (br t, J=5.7 Hz, 1H), 7.27-7.39 (m, 5H).
  • Compound 26
  • Figure US20110160459A1-20110630-C00058
    • N-[(3-Dimethylamino)-2,2-dimethylpropyl]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.92 Hz, 3H), 0.94 (s, 3H), 0.95 (s, 3H), 1.17-1.34 (m, 4H), 1.58-1.70 (m, 2H), 2.26 (s, 2H), 2.33 (s, 6H), 2.78-2.94 (m, 3H), 3.24 (d, J=5.4 Hz, 2H), 3.40 (dd, J=17.1 and 10.8 Hz, 1H), 4.35 (dd, J=14.6 and 11 Hz, 1H), 7.28-7.41 (m, 5H), 8.58 (br s, 1H).
  • Compound 27
  • Figure US20110160459A1-20110630-C00059
    • N-(Adamantyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.92 Hz, 3H), 1.15-1.32 (m, 4H) 1.49-1.64 (m, 2H), 1.65-1.76 (m, 7H), 2.08 (br s, 8H), 2.78 (dd, J=17.1 and 14.4 Hz, 1H), 2.89 (t, J=7.5 Hz, 2H), 3.37 (dd, J=17.3 and 11 Hz, 1H) 4.35 (dd, J=14.6 and 11 Hz, 1H), 6.40 (br s, 1H), 7.27-7.41 (m, 5H).
  • Compound 28
  • Figure US20110160459A1-20110630-C00060
    • N-(1-Phenyl-1-methyl-ethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 1.16-1.33 (m, 4H), 1.51-1.69 (m, 2H), 1.75 (s, 3H), 1.77 (s, 3H), 2.78 (dd, J=17.3 and 14.6 Hz, 1H), 2.92 (br t, J=7.1 Hz, 2H), 3.35 (dd, J=17.3 and 11 Hz, 1H), 4.38 (dd, J=14.4 and 11.1 Hz, 1 H), 6.97 (br s, 1H), 7.19-7.24 (m, 1H), 7.27-7.41 (m, 7H), 7.45 (br d, J=7.2 Hz, 2H).
  • Compound 29
  • Figure US20110160459A1-20110630-C00061
    • N—(N,2,2,6,6-pentamethylpiperidin-4-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7.1 Hz, 3H), 1.10 (s, 6H). 1.16 (s, 6H). 1.19-1.30 (m, 4H). 1.37 (br t, J=11.4 Hz, 2H), 1.50-1.68 (m, 2H), 1.86 (dd, J=12.3 and 3.3 Hz, 2H), 2.26 (s, 3H), 2.81 (dd, J=17.5 and 14.4 Hz, 1H), 2.86-2.97 (m, 2H), 3.40 (dd, J=17.1 and 11.1 Hz, 1H), 4.14-4.30 (m, 1H), 4.39 (dd, J=14.4 and 11.1 Hz, 1H), 6.39 (br d, J=8.1 Hz, 1H), 7.27-7.40 (m, 5H).
  • Compound 30
  • Figure US20110160459A1-20110630-C00062
    • N-Methyl-N-(Naphthalen-1-yl-methyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) (broad signals due to restricted amide bond rotation) δ 0.56-1.78 (m, 9H), 2.48-3.08 (m, 3H), 3.10 (br s) and 3.26 (br s: Together integrates for 3H), 3.40-3.59 (m, 1H), 4.15-4.40 (m, 1H), 5.18 (br s) and 5.50 (br d, J=16 Hz) and 5.64 (br d, J=16 Hz; Together integrates for 2H), 7.26-7.58 (m, 9H), 7.80 (br s, 1H), 7.88 (br d, J=7 Hz, 1H), 7.92-8.17 (m, 1H),
  • Compound 31
  • Figure US20110160459A1-20110630-C00063
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-pentyl)-5-(pyrid-2-yl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, DMSO-d6) δ 0.81-0.95 (m, 10H), 0.97 (s, 3H), 1.16-1.35 (m, 4H), 1.35-1.66 (m, 5H), 1.69 (t, J=4.4 Hz, 1H), 1.74-1.87 (m, 1H), 2.32-2.44 (m, 1H), 2.91-3.11 (m, 3H), 3.44-3.59 (m, 1H), 4.24-4.35 (m, 1H), 4.54-4.67 (m, 1H), 6.69 (br d, J=8.4 Hz, 1H), 7.20-7.27 (m, 1H), 7.46 (dd, J=7.8 and 4.5 Hz, 1 H), 7.72 (br t, J=7.5 Hz, 1H), 8.58 (br t, J=4 Hz, 1H).
  • Compound 32
  • Figure US20110160459A1-20110630-C00064
    • N-(1-Phenyl-1-methyl-ethyl)-1-(n-pentyl)-5-(pyrid-2-yl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, DMSO-d6) δ 0.84 (t, J=6.9 Hz, 3H), 1.17-1.31 (m, 4 H), 1.52-1.65 (m, 2H), 1.73 (s, 3H), 1.75 (s, 3H), 2.88-3.10 (m, 3H), 3.40 (dd, J=17.3 and 11.6 Hz, 1H), 4.59 (dd, J=13.67 and 11.6 Hz, 1H), 7.02 (br s, 1H), 7.19-7.28 (m, 2H), 7.33 (br t, J=7.7 Hz, 2H), 7.40-7.48 (m, 3H), 7.74 (dt, J=7.7 and 1.8 Hz, 1H), 8.57 (br d, J=3.9 Hz, 1H).
  • Compound 33
  • Figure US20110160459A1-20110630-C00065
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-(3-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 1)
  • Compounds 33 and 34 were separated from the corresponding diastereomeric mixture by flash chromatography (silicagel). Eluant: petroleum ether (40-60)/diethyl ether=4/1 v/v).
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.95 (m, 10H), 0.97 (s, 3H), 1.20-1.48 (m, 4H), 1.52-1.63 (m, 3H), 1.69 (t, J=4.5 Hz, 1H), 1.74-1.86 (m, 1H), 2.32-2.43 (m, 1H), 2.78 (dd, J=17.4 and 14.1 Hz, 1H), 2.95 (t, J=7.4 Hz, 2H), 3.38-3.48 (m, 1H) 4.25-4.34 (m, 1H), 4.38 (dd, J=14.1 and 11.4 Hz, 1H), 6.66 (br d, J=9.3 Hz, 1H), 7.20-7.39 (m, 4H).
  • Compound 34
  • Figure US20110160459A1-20110630-C00066
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-(3-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 2)
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.95 (m, 10H), 0.97 (s, 3H), 1.21-1.47 (m, 4H) 1.51-1.65 (m, 3H), 1.69 (t, J=4.3 Hz, 1H), 1.75-1.86 (m, 1H), 2.33-2.43 (m, 1H), 2.79 (dd, J=17.3 and 14.3 Hz, 1H), 2.94 (t, J=7.2 Hz, 2H), 3.42 (dd, J=17.4 and 11.1 Hz, 1H), 4.26-4.41 (m, 2H), 6.65 (d, J=9 Hz, 1H), 7.23-7.31 (m, 3 H), 7.39 (br s, 1H).
  • Compound 35
  • Figure US20110160459A1-20110630-C00067
    • N-(1-Phenyl-1-methyl-ethyl)-1-(n-butyl)-5-(3-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.87 (t, J=7.4 Hz, 3H), 1.21-1.43 (m, 2H), 1.54-1.64 (m, 2H), 1.75 (s, 3H), 1.77 (s, 3H), 2.74 (dd, J=17.4 and 14.1 Hz, 1H), 2.93 (t, J=7.3 Hz, 2H), 3.36 (dd, J=17.1 and 11.1 Hz, 1H), 4.35 (dd, J=14.3 and 11.3 Hz, 1H), 6.96 (br s, 1H), 7.21-7.30 (m, 4H), 7.31-7.38 (m, 3H), 7.45 (br d, J=8.1 Hz, 2H).
  • Compound 36
  • Figure US20110160459A1-20110630-C00068
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-(n-butyl)-5-(3-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ0.87 (t, J=7.4 Hz, 3H), 1.21-1.41 (m, 2H), 1.54-1.64 (m, 2H), 1.74 (s, 3H), 1.75 (s, 3H), 2.73 (dd, J=17.4 and 14.4 Hz, 1H), 2.93 (t, J=7.4 Hz, 2H), 3.35 (dd, J=17.3 and 11.3 Hz, 1H), 4.35 (dd, J=14.1 and 11.1 Hz, 1H), 6.93 (br s, 1H), 7.01 (br t, J=8.7 Hz, 2H), 7.21-7.31 (m, 3H), 7.36-7.44 (m, 3H).
  • Compound 37
  • Figure US20110160459A1-20110630-C00069
    • N-(1-Phenyl-1-methyl-ethyl)-1-(n-butyl)-trans-4-methyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • A Sepacore chromatographic purification was applied to purify the crude compound 37: Eluant: Dichloromethane.
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7.4 Hz, 3H), 1.19-1.38 (m, 5H), 1.51-1.61 (m, 2H), 1.74 (s, 3H), 1.77 (s, 3H), 2.89-2.97 (m, 2H), 3.14 (dq, J=13.4 and 6.7 Hz, 1H), 3.84 (d, J=13.2 Hz, 1H), 6.98 (br s, 1H), 7.23 (br t, J=7.4 Hz, 1H), 7.28-7.39 (m, 7H), 7.45 (br d, J=7.2 Hz, 2H).
  • Compound 38
  • Figure US20110160459A1-20110630-C00070
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-trans-4-methyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • Two successive Sepacore chromatographic purifications were applied to isolate compound 38 from the crude reaction mixture: Separation A: Eluant: petroleum ether (40-60)/diethyl ether=80/20. Separation B: Eluant: petroleum ether (40-60)/ethylacetate=90/10.
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.94 (m, 10H), 0.97 (s, 3H) 1.21-1.47 (m, 6H), 1.50-1.67 (m, 4H), 1.69 (t, J=4.5 Hz, 1H), 1.74-1.86 (m, 1H), 2.32-2.44 (m, 1H), 2.88-3.02 (m, 2H), 3.13-3.25 (m, 1H), 3.81-3.90 (m, 1H), 4.22-4.36 (m, 1H), 6.64-6.73 (m, 1H), 7.29-7.41 (m, 5H).
  • Compound 39
  • Figure US20110160459A1-20110630-C00071
    • N-(Endo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7.1 Hz, 3H), 1.16-1.38 (m, 7H), 1.40-1.68 (m, 6H), 2.06-2.17 (m, 1H), 2.24 (br s, 1H), 2.49 (br s, 1H), 2.82 (dd, J=16.5 and 14.4 Hz, 1H), 2.88-3.01 (m, 2H), 3.41 (dd, J=17.1 and 11.1 Hz, 1H), 4.13-4.24 (m, 1H), 4.35-4.47 (m, 1H), 6.60-6.73 (m, 1H), 7.28-7.43 (m, 5H).
  • Compounds 40-43
  • Figure US20110160459A1-20110630-C00072
  • Compound 12 was separated by preparative chiral HPLC into 4 separate stereoisomers (compounds 40, 41, 42 and 43, respectively).
  • N-(Exo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (compound 40) (stereoisomer 1; first eluting diastereomer; retention time=10.29 minutes; Diastereomeric excess=97%): [α25 D]=+147°, c=0.9, methanol.
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7 Hz, 3H), 1.10-1.66 (m, 15H), 1.83 (ddd, J=13, 8 and 2.1 Hz, 1H), 2.25-2.33 (m, 2H), 2.81 (dd, J=17.3 and 14.3 Hz, 1H), 2.86-2.97 (m, 2H), 3.40 (dd, J=17.4 and 11.1 Hz, 1H), 3.79 (br td, J=7.6 and 3.4 Hz, 1H), 4.37 (dd, J=14.30 and 11 Hz, 1H), 6.45 (br d, J=7.5 Hz, 1H), 7.27-7.40 (m, 5H).
  • N-(Exo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (compound 41) (stereoisomer 2; second eluting diastereomer; retention time=12.57 minutes; Diastereomeric excess>99%): [α25 D]=+158°, c=1.1, methanol.
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7 Hz, 3H), 1.11-1.65 (m, 15H), 1.83 (ddd, J=13, 8 and 2.1 Hz, 1H), 2.26-2.33 (m, 2H), 2.81 (dd, J=17.3 and 14.3 Hz, 1H), 2.86-2.98 (m, 2H), 3.40 (dd, J=17.4 and 11.1 Hz, 1H), 3.79 (br td, J=7.6 and 3.4 Hz, 1H), 4.38 (dd, J=14.4 and 11.1 Hz, 1H), 6.45 (br d, J=7.2 Hz, 1H), 7.27-7.38 (m, 5H).
  • N-(Exo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (compound 42) (stereoisomer 3; third eluting diastereomer; retention time=13.71 minutes; Diastereomeric excess>99%) [α25 D]=−173°, c=1.0, methanol.
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7 Hz, 3H), 1.10-1.66 (m, 15H), 1.83 (ddd, J=13, 8 and 2.1 Hz, 1H), 2.24-2.34 (m, 2H), 2.81 (dd, J=17.3 and 14.3 Hz, 1H), 2.86-2.98 (m, 2H), 3.40 (dd, J=17.4 and 11.1 Hz, 1H), 3.79 (br td, J=7.6 and 3.4 Hz, 1H), 4.38 (dd, J=14.2 and 11.1 Hz, 1H), 6.45 (br d, J=7.5 Hz, 1H), 7.27-7.37 (m, 5H).
  • N-(Exo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (compound 43) (stereoisomer 4; fourth eluting diastereomer; retention time=23.01 minutes; Diastereomeric excess>99%): [α25 D]=−162°, c=0.9, methanol.
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7 Hz, 3H), 1.10-1.66 (m, 15H), 1.83 (ddd, J=12.9, 8.1 and 2.1 Hz, 1H), 2.25-2.34 (m, 2H), 2.81 (dd, J=17.2 and 14.4 Hz, 1H), 2.85-2.98 (m, 2H), 3.40 (dd, J=17.2 and 11.1 Hz, 1H), 3.79 (br td, J=7.6 and 3.6 Hz, 1H), 4.37 (dd, J=14.2 and 11.1 Hz, 1H), 6.45 (br d, J=7.2 Hz, 1H), 7.27-7.40 (m, 5H).
  • Preparative chiral HPLC method: First step: A 250×30 mm column was used. Stationary phase: CHIRALPAK® AD=H 5 μm. n-Heptane/isopropanol=95/05 (v/v) was used as the mobile phase. Flow rate: 40 ml/minute. Temperature: 21.5° C. Detection UV 325 nm. Second step: A 250×30 mm column was used. Stationary phase: CHIRALPAK® IA 5 μm. n-Heptane/ethylacetate=85/15 (v/v) was used as the mobile phase. Flow rate: 40 ml/minute. Temperature: ambient. Detection UV 325 nm.
  • Analytical HPLC monitoring system: A 250×4.6 mm column was used. Stationary phase: CHIRALPAK® IA-H 5 μm. n-Heptane/ethylacetate=80/20 (v/v) was used as the mobile phase. Flow rate: 1 ml/minute. Temperature: 25° C. Detection: UV 300 nm.
  • Compounds 44-45
  • Figure US20110160459A1-20110630-C00073
  • Racemic compound 22 (1.88 gram) was separated by preparative chiral HPLC into 2 separate enantiomers (compounds 44 and 45, respectively).
    • (+)-N-[3-(Trifluoromethyl)benzyl)]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (compound 44)
  • [α25 D]=124°, c=1.0, methanol. 1H-NMR (400 MHz, CDCl3) δ 0.83 (t, J=6.92 Hz, 3H), 1.15-1.30 (m, 4H), 1.51-1.65 (m, 2H), 2.81-2.99 (m, 3H), 3.45 (dd, J=17.3 and 11.3 Hz, 1H), 4.46 (dd, J=14.4 and 11.4 Hz, 1H), 4.59 (s, 2H), 7.28-7.39 (m, 5H), 7.43-7.50 (m, 1H), 7.52-7.60 (m, 3H). Enantiomeric excess: >98%.
    • (−)-N-[3-(Trifluoromethyl)benzyl)]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (compound 45)
  • [α25 D]=−132°, c=0.8, methanol. 1H-NMR (400 MHz, CDCl3) δ 0.83 (t, J=6.92 Hz, 3H), 1.15-1.30 (m, 4H), 1.51-1.65 (m, 2H), 2.81-2.99 (m, 3H), 3.45 (dd, J=17.3 and 11.3 Hz, 1H), 4.46 (dd, J=14.4 and 11.4 Hz, 1H), 4.59 (s, 2H), 7.28-7.39 (m, 5H), 7.43-7.50 (m, 1H), 7.52-7.60 (m, 3H). Enantiomeric excess: >98%.
  • Preparative chiral HPLC method: A 250×76 mm column was used. Stationary phase: CHIRALPAK® IA 20 μm. n-Heptane/dichloromethane=75/25 (v/v) was used as the mobile phase. Flow rate: 270 ml/minute. Temperature: 25° C. Detection UV 300 nm
  • Analytical HPLC monitoring system: A 250×4.6 mm column was used. Stationary phase: CHIRALPAK® IA-H 5 μm. n-Heptane/dichloromethane=75/25 (v/v) was used as the mobile phase. Flow rate: 1 ml/minute. Temperature: 25° C. Detection: Diode array detection (DAD) 254 and 300 nm.
  • Enantiomeric excess: >98%
  • Compound 46
  • Figure US20110160459A1-20110630-C00074
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-pentyl)-5-(4-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.94 (m, 10H), 0.97 (s, 3H), 1.07-1.47 (m, 7H), 1.52-1.65 (m, 2H), 1.69 (t, J=4.4 Hz, 1H), 1.75-1.86 (m, 1H), 2.33-2.43 (m, 1H), 2.73-2.84 (m, 1H), 2.88-2.96 (m, 2H), 3.35-3.51 (m, 1H), 4.26-4.44 (m, 2H), 6.67 (br d, J=6 Hz, 1H), 7.04 (t, J=8.4 Hz, 2H), 7.31-7.39 (m, 2H).
  • Compound 47
  • Figure US20110160459A1-20110630-C00075
    • N-[3-(trifluoromethyl)benzyl]-1-(n-pentyl)-5-(3-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.91 (m, 3H), 1.16-1.35 (m, 4H), 1.52-1.65 (m, 2H), 2.84 (dd, J=17.4 and 14.1 Hz, 1H), 2.87-2.99 m, 2H), 3.46 (dd, J=17.4 and 11.4 Hz, 1H), 4.45 (dd, J=14.1 and 11.4 Hz, 1H), 4.60 (d, J=6.3 Hz, 2H), 7.01 (dt, J=8.1 and 2.1 Hz, 2H), 7.07-7.16 (m, 2H), 7.33 (dt, J=7.9 and 5.8 Hz, 1H), 7.43-7.50 (m, 1H), 7.51-7.61 (m, 3H).
  • Compound 48
  • Figure US20110160459A1-20110630-C00076
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-(n-pentyl)-5-(3-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.90 (m, 3H), 1.22-1.34 (m, 4H), 1.54-1.67 (m, 2H), 1.73 (s, 3H), 1.74 (s, 3H), 2.73 (dd, J=17.4 and 14.1 Hz, 1H), 2.93 (t, J=7.4 Hz, 2H), 3.35 (dd, J=17.4 and 11.1 Hz, 1H), 4.38 (dd, J=14.3 and 11.3 Hz, 1H), 6.94 (br s, 1H), 6.96-7.05 (m, 3H), 7.07-7.14 (m, 2H), 7.28-7.35 (m, 1H), 7.37-7.44 (m, 2H).
  • Compound 49
  • Figure US20110160459A1-20110630-C00077
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-(n-pentyl)-5-(4-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.90 (m, 3H), 1.20-1.31 (m, 4H), 1.53-1.67 (m, 2H), 1.73 (s, 3H), 1.74 (s, 3H), 2.73 (dd, J=17.4 and 14.4 Hz, 1H), 2.91 (t, J=7.4 Hz, 2H), 3.33 (dd, J=17.4 and 11.1 Hz, 1H), 4.36 (dd, J=14.1 and 11.1 Hz, 1H), 6.95 (br s, 1H), 6.97-7.08 (m, 4H), 7.33 (dd, J=8.7 and 5.4 Hz, 2H), 7.41 (dd, J=8.9 and 5.3 Hz, 2H).
  • Compound 50
  • Figure US20110160459A1-20110630-C00078
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-(n-propyl)-5-(3-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.89 (t, J=7.4 Hz, 3H), 1.55-1.71 (m, 2H), 1.73 (s, 3H), 1.74 (s, 3H), 2.73 (dd, J=17.3 and 14.3 Hz, 1H), 2.83-2.97 (m, 2H), 3.36 (dd, J=17.4 and 11.1 Hz, 1H), 4.38 (dd, J=14.3 and 11.3 Hz, 1H), 6.94 (brs, 1H), 6.96-7.05 (m, 3H), 7.07-7.15 (m, 2H), 7.28-7.35 (m, 1H), 7.40 (dd, J=8.7 and 5.4 Hz, 2H).
  • Compound 51
  • Figure US20110160459A1-20110630-C00079
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(4,4,4-trifluorobutyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 1)
  • Compounds 51 and 52 were obtained from the corresponding diasteromeric mixture via a flash chromatographic purification (silicagel). Eluant: petroleum ether (40-60)/ethylacetate=90/10 (v/v). Compound 52: second (slowest) eluting diastereomer: Compound 51: first (fastest) eluting diastereomer.
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.95 (m, 7H), 0.98 (s, 3H), 1.22-2.11 (m, 8H), 2.13-2.27 (m, 1H), 2.34-2.45 (m, 1H), 2.81-2.96 (m, 2H), 2.99-3.08 (m, 1H), 3.44 (dd, J=17.4 and 11.1 Hz, 1H), 4.26-4.40 (m, 2H), 6.65 (br d, J=9 Hz, 1H), 7.30-7.42 (m, 5H). [α25 D]=102°, c=1, methanol.
  • Compound 52
  • Figure US20110160459A1-20110630-C00080
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(4,4,4-trifluorobutyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 2)
  • 1H-NMR (400 MHz, CDCl3) δ 0.83-0.94 (m, 7H), 0.97 (s, 3H), 1.20-1.32 (m, 1H), 1.38-1.49 (m, 1H), 1.54-1.63 (m, 1H), 1.70 (t, J=4.4 Hz, 1H), 1.75-1.88 (m, 2H), 1.89-2.08 (m, 2H), 2.13-2.29 (m, 1H), 2.32-2.44 (m, 1H), 2.81-2.95 (m, 2H), 2.97-3.07 (m, 1H), 3.42 (dd, J=17.4 and 10.8 Hz, 1H), 4.26-4.38 (m, 2H), 6.65 (br d, J=9.3 Hz, 1H), 7.29-7.41 (m, 5H). [α25 D]=−102°, c=1, methanol.
  • Compound 53
  • Figure US20110160459A1-20110630-C00081
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-propyl-5-(3-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 1)
  • Compounds 53 and 54 were obtained from the corresponding diasteromeric mixture via a flash chromatographic purification (silicagel). Eluant gradient: petroleum ether (40-60)/ethylacetate=95/5=>petroleum ether (40-60)/ethylacetate=90/10 (v/v). Compound 53: second (slowest) eluting diastereomer: Compound 54: first (fastest) eluting diastereomer.
  • 1H-NMR (400 MHz, CDCl3) δ 0.83-0.94 (m, 10H), 0.97 (s, 3H), 1.21-1.30 (m, 1H), 1.36-1.47 (m, 1H), 1.54-1.73 (m, 4H), 1.74-1.86 (m, 1H), 2.31-2.43 (m, 1H), 2.80 (dd, J=17.3 and 14.3 Hz, 1H), 2.85-2.99 (m, 2H), 3.43 (dd, J=17.4 and 11.1 Hz, 1H), 4.25-4.35 (m, 1H), 4.38 (dd, J=14.1 and 11.1 Hz, 1H) 6.66 (br d, J=9 Hz, 1H) 7.00 (br t, J=8.3 Hz, 1H), 7.09-7.18 (m, 2H), 7.28-7.37 (m, 1H). [α25 D]=−122°, c=1, methanol.
  • Compound 54
  • Figure US20110160459A1-20110630-C00082
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-propyl-5-(3-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 2)
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.93 (m, 10H), 0.97 (s, 3H), 1.21-1.31 (m, 1H), 1.37-1.47 (m, 1H), 1.54-1.67 (m, 3H), 1.69 (t, J=4.4 Hz, 1H), 1.74-1.86 (m, 1H), 2.31-2.43 (m, 1H), 2.79 (dd, J=17.4 and 14.1 Hz, 1H), 2.85-2.99 (m, 2 H), 3.44 (dd, J=17.1 and 11.1 Hz, 1H), 4.30 (br tt, J=9.1 and 2.4 Hz, 1H), 4.40 (dd, J=14.0 and 11.3 Hz, 1H), 6.66 (br d, J=9 Hz, 1H), 7.00 (dt, J=8.3 and 1.9 Hz, 1H), 7.08-7.15 (m, 2H), 7.31 (dd, J=7.8 and 6 Hz, 1H). [α25 D]=145°, c=1, methanol.
  • Compound 55
  • Figure US20110160459A1-20110630-C00083
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-(4,4,4-trifluorobutyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 1.74 (s, 3H), 1.75 (s, 3H), 1.78-1.88 (m, 1 H), 1.89-2.06 (m, 2H), 2.14-2.26 (m, 1H), 2.80 (dd, J=17.4 and 14.4 Hz, 1H), 2.85-2.93 (m, 1H), 2.98-3.06 (m, 1H), 3.35 (dd, J=17.4 and 10.8 Hz, 1H), 4.32 (dd, J=14.6 and 11 Hz, 1H), 6.93 (br s, 1H), 7.02 (t, J=8.7 Hz, 2H), 7.29-7.38 (m, 5H), 7.38-7.44 (m, 2H).
  • Compound 56
  • Figure US20110160459A1-20110630-C00084
    • N-Cyclohexylmethyl-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7, 3 H), 0.91-1.03 (m, 2H), 1.10-1.34 (m, 7H), 1.47-1.70 (m, 4H), 1.70-1.81 (m, 4H), 2.80 (dd, J=17.1 and 13.8 Hz, 1H), 2.88-3.01 (m, 2H), 3.12-3.25 (m, 2H), 3.48 (dd, J=17.1 and 11.4 Hz, 1 H), 4.73 (dd, J=13.8 and 11.4 Hz, 1H), 6.67 (br t, J ˜6.5 Hz, 1H), 7.05 (dd, J=10.1 and 8.6 Hz, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.24-7.31 (m, 1H), 7.48 (dt, J=7.5 and ˜2 Hz, 1H).
  • Compound 57
  • Figure US20110160459A1-20110630-C00085
    • N-(Indan-2-yl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.86 (m, 3H), 1.13-1.31 (m, 4H) 1.51-1.64 (m, 2H), 2.81 (dd, J=17.4 and 13.8 Hz, 1H), 2.86-2.97 (m, 4H), 3.32-3.41 (m, 2 H), 3.49 (dd, J=17.1 and 11.4 Hz, 1H), 4.74 (dd, J=13.7 and 11.6 Hz, 1H), 4.78-4.87 (m, 1H), 6.78 (br d, J=8.1 Hz, 1H), 7.01-7.08 (m, 1H) 7.12-7.17 (m, 1H), 7.17-7.22 (m, 2H), 7.22-7.31 (m, 3H), 7.42-7.49 (m, 1H).
  • Compound 58
  • Figure US20110160459A1-20110630-C00086
    • N-(Endo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.89 (m, 4H), 1.20-1.38 (m, 6H), 1.43-1.52 (m, 2H), 1.53-1.70 (m, 4H), 2.06-2.17 (m, 1H), 2.24 (br t, J=4.5 Hz, 1H), 2.49 (br t, J=4.3 Hz, 1H), 2.79 (dd, J=17.3 and 13.7 Hz, 1H), 2.89-3.03 (m, 2H), 3.48 (dd, J=17.4 and 11.4 Hz, 1H), 4.13-4.23 (m, 1H), 4.70-4.78 (m, 1H), 6.63-6.69 (m, 1H), 7.02-7.08 (m, 1H), 7.13-7.18 (m, 1H), 7.24-7.31 (m, 1H), 7.45-7.52 (m, 1H).
  • Compound 59
  • Figure US20110160459A1-20110630-C00087
    • N-(Cycloheptyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7 Hz, 3H), 1.20-1.32 (m, 4H), 1.46-1.71 (m, 11H), 1.92-2.03 (m, 2H), 2.74-2.84 (m, 2H), 2.90-2.98 (m, 2H), 3.47 (dd, J=17.1 and 11.4 Hz, 1H), 3.96-4.07 (m, 1H), 4.72 (dd, J=13.8 and 11.1 Hz, 1H), 6.56 (br d, J=8.4 Hz, 1H), 7.01-7.08 (m, 1H), 7.12-7.18 (m, 1H), 7.24-7.31 (m, 1H), 7.46-7.51 (m, 1H).
  • Compound 60
  • Figure US20110160459A1-20110630-C00088
    • N-[3,4-difluorobenzyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 1.17-1.33 (m, 4H), 1.54-1.70 (m, 2H), 2.84 (dd, J=17.3 and 13.7 Hz, 1H), 2.88-3.02 (m, 2H), 3.50 (dd, J=17.3 and 11.6 Hz, 1H), 4.43-4.54 (m, 2H), 4.79 (dd, J=13.8 and 11.7 Hz, 1H), 6.96 (br t, J=6.3 Hz, 1H), 7.02-7.20 (m, 5H), 7.25-7.32 (m, 1H), 7.47 (dt, J=7.5 and 1.8 Hz, 1H).
  • Compound 61
  • Figure US20110160459A1-20110630-C00089
    • N-[Naphthalen-1-ylmethyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.80 (t, J=6.9 Hz, 3H), 1.21 (m, 4H), 1.49-1.61 (m, 2H), 2.79-2.97 (m, 3H), 3.53 (dd, J=17.1 and 11.4 Hz, 1H), 4.71-4.80 (m, 1 H), 4.95-5.06 (m, 2H), 6.84-6.90 (m, 1H) m 7.02-7.08 (m, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.24-7.31 (m, 1H), 7.42-7.61 (m, 5H), 7.83 (d, J=8.1 Hz, 1H), 7.90 (d, J=8.1 Hz, 1H), 8.10 (d, J=8.1 Hz, 1H).
  • Compound 62
  • Figure US20110160459A1-20110630-C00090
    • N-[2-(Indol-3-yl)ethyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=6.9 Hz, 3H), 1.17-1.32 (m, 4H), 1.52-1.64 (m, 2H), 2.81 (dd, J=17.3 and 13.7 Hz, 1H), 2.86-2.98 (m, 2H), 3.04 (t, J=6.9 Hz, 2H), 3.48 (dd, J=17.1 and 11.4 Hz, 1H), 3.68 (q, J=6.6 Hz, 2H), 4.68-4.78 (m, 1H), 6.77 (br t, J=6.2 Hz, 1H), 7.01-7.10 (m, 2H), 7.14 (q, J=7.1 Hz, 2H), 7.21 (t, J=7.5 Hz, 1H), 7.24-7.31 (m, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.43-7.49 (m, 1H), 7.65 (d, J=7.8 Hz, 1H), 8.06 (br s, 1H).
  • Compound 63
  • Figure US20110160459A1-20110630-C00091
    • N-[(Pyridin-3-yl)methyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.89 (m, 3H), 1.15-1.33 (m, 4H), 1.53-1.69 (m, 2H), 2.84 (dd, J=17.3 and 13.7 Hz, 1H), 2.89-3.02 (m, 2H), 3.50 (dd, J=17.3 and 11.6 Hz, 1H), 4.51-4.60 (m, 2H) 4.79 (dd, J=13.8 and 11.4 Hz, 1H), 6.98 (br t, J=6.5 Hz, 1H), 7.03-7.09 (m, 1H), 7.16 (t, J=7 Hz, 1H), 7.24-7.34 (m, 2H), 7.46 (dt, J=7.5 and 2 Hz, 1H), 7.69 (br d, J=7.8 Hz, 1H), 8.54 (br d, J=4.8 Hz, 1H), 8.58-8.62 (m, 1H).
  • Compound 64
  • Figure US20110160459A1-20110630-C00092
    • N-[2-(Thien-2-yl)ethyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84-0.90 (m, 3H), 1.18-1.34 (m, 4H), 1.56-1.67 (m, 2H), 2.80 (dd, J=17.1 and 13.8 Hz, 1H), 2.86-3.01 (m, 2H), 3.10 (t, J=6.9 Hz, 2H), 3.48 (dd, J=17.1 and 11.4 Hz, 1H), 3.62 (q, J=6.6 Hz, 2H), 4.75 (dd, J=13.8 and 11.4 Hz, 1H), 6.79 (br t, J=6.3 Hz, 1H), 6.88 (dd, J=3.2 and 1 Hz, 1H), 6.96 (dd, J=5.1 and 3.3 Hz, 1H), 7.02-7.09 (m, 1H), 7.13-7.19 (m, 2H), 7.24-7.31 (m, 1H), 7.44-7.50 (m, 1H).
  • Compound 65
  • Figure US20110160459A1-20110630-C00093
    • N-[3,3-diphenylpropyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.87 (t, J=6.9 Hz, 3H), 1.20-1.34 (m, 4H), 1.55-1.69 (m, 2H), 2.31-2.39 (m, 2H), 2.77 (dd, J=17.4 and 13.8 Hz, 1H), 2.85-2.99 (m, 2H), 3.31 (q, J=8 Hz, 2H), 3.45 (dd, J=17.1 and 11.4 Hz, 1H), 4.00 (t, J=7.8 Hz, 1 H), 4.72 (dd, J=14 and 11.23 Hz, 1H), 6.59 (br t, J=6.6 Hz, 1H), 7.01-7.09 (m, 1H), 7.13-7.20 (m, 3H), 7.24-7.31 (m, 9H), 7.47 (dt, J=7.5 and 2 Hz, 1H).
  • Compound 66
  • Figure US20110160459A1-20110630-C00094
    • N-[(Furan-2-yl)methyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.90 (m, 3H), 1.17-1.35 (m, 4H), 1.54-1.69 (m, 2H), 2.82 (dd, J=17.3 and 13.7 Hz, 1H), 2.87-3.01 (m, 2H), 3.49 (dd, J=17.3 and 11.6 Hz, 1H), 4.48-4.60 (m, 2H), 4.76 (dd, J=13.7 and 11.6 Hz, 1H), 6.26-6.37 (m, 2H), 6.90 (br t, J=6 Hz, 1H), 7.02-7.09 (m, 1H), 7.12-7.18 (m, 1H), 7.24-7.32 (m, 1H), 7.36-7.40 (m, 1H), 7.46 (dt, J=8.2 and 2 Hz, 1H).
  • Compound 67
  • Figure US20110160459A1-20110630-C00095
    • N-Benzyl-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.9 Hz, 3H), 1.17-1.32 (m, 4H), 1.54-1.66 (m, 2H), 2.84 (dd, J=17.1 and 13.8 Hz, 1H), 2.86-3.00 (m, 2H), 3.51 (dd, J=17.4 and 11.4 Hz, 1H), 4.50-4.58 (m, 2H), 4.76 (dd, J=13.8 and 11.4 Hz, 1H), 6.92 (br t, J=6 Hz, 1H), 7.02-7.09 (m, 1H), 7.16 (dt, J=7.5 and 1.2 Hz, 1H), 7.25-7.32 (m, 3H), 7.33-7.39 (m, 3H), 7.47 (dt, J=7.1 and 1.3 Hz, 1H).
  • Compound 68
  • Figure US20110160459A1-20110630-C00096
    • N-Cyclopentyl-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=6.9 Hz, 3H), 1.18-1.35 (m, 4H), 1.41-1.53 (m, 2H), 1.55-1.80 (m, 6H), 1.97-2.10 (m, 2H), 2.79 (dd, J=17.4 and 13.8 Hz, 1H), 2.87-3.01 (m, 2H), 3.48 (dd, J=17.4 and 11.4 Hz, 1H), 4.27 (sextet, J=7.1 Hz, 1H), 4.72 (dd, J=14 and 11.3 Hz, 1H), 6.54 (br d, J=7.8 Hz, 1H), 7.05 (dd, J=11 and 7.7 Hz, 1H), 7.15 (t, J=7.4 Hz, 1H), 7.24-7.32 (m, 1H), 7.48 (dt, J=7.4 and 1.6 Hz, 1H).
  • Compound 69
  • Figure US20110160459A1-20110630-C00097
    • N-(4-Methoxybenzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.9 Hz, 3H), 1.17-1.32 (m, 4H), 1.54-1.67 (m, 2H), 2.82 (dd, J=17.4 and 13.8 Hz, 1H), 2.87-2.99 (m, 2H), 3.50 (dd, J=17.1 and 11.4 Hz, 1H), 3.81 (s, 3H), 4.46-4.49 (m, 2H), 4.75 (dd, J=14.1 and 11.4 Hz, 1H), 6.82-6.91 (m, 3H), 7.05 (dd, J=11 and 7.7 Hz, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.24-7.31 (m, 3H), 7.47 (dt, J=7.5 and 1.8 Hz, 1H).
  • Compound 70
  • Figure US20110160459A1-20110630-C00098
    • N-(2-Methoxybenzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=6.9 Hz, 3H), 1.18-1.33 (m, 4H), 1.56-1.67 (m, 2H), 2.80 (dd, J=17.1 and 13.8 Hz, 1H), 2.86-2.99 (m, 2H), 3.49 (dd, J=17.1 and 11.4 Hz, 1H), 3.88 (s, 3H), 4.52-4.56 (m, 2H), 4.73 (dd, J=14 and 11.3 Hz, 1H), 6.87-6.96 (m, 2H), 7.05 (dd, J=9.8 and 8.9 Hz, 1H), 7.08-7.18 (m, 2H), 7.23-7.34 (m, 3H), 7.47 (dt, J=7.6 and 2 Hz, 1H).
  • Compound 71
  • Figure US20110160459A1-20110630-C00099
    • N-[(1-ethyl)propyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.89 (m, 3H), 0.90-0.98 (m, 6H), 1.19-1.34 (m, 4H), 1.39-1.53 (m, 2H), 1.54-1.70 (m, 4H), 2.81 (dd, J=17.1 and 13.8 Hz, 1H), 2.89-3.03 (m, 2H), 3.49 (dd, J=17.3 and 11.23 Hz, 1H), 3.79-3.91 (m, 1H), 4.75 (dd, J=13.8 and 11.4 Hz, 1H), 6.38 (br d, J=9.3 Hz, 1H), 7.01-7.09 (m, 1H), 7.16 (t, J=7.5 Hz, 1H), 7.24-7.32 (m, 1H), 7.49 (dt, J=7.5 and 1.8 Hz, 1H).
  • Compound 72
  • Figure US20110160459A1-20110630-C00100
    • N-(Exo-bicyclo[2.2.1]hept-2-yl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=6.9 Hz, 3H), 1.11-1.19 (m, 1H), 1.19-1.33 (m, 7H), 1.38-1.69 (m, 5H), 1.79-1.87 (m, 1H), 2.26-2.33 (m, 2H), 2.79 (dd, J=17.4 and 13.8 Hz, 1H), 2.88-3.01 (m, 2H), 3.47 (dd, J=17.4 and 11.4 Hz, 1H), 3.79 (dt, J=7.7 and 3.4 Hz, 1H), 4.68-4.77 (m, 1H), 6.48 (br d, J=7.5 Hz, 1H), 7.05 (dd, J=9.8 and 8.6 Hz, 1H), 7.12-7.18 (m, 1H), 7.24-7.31 (m, 1H), 7.44-7.51 (m, 1H).
  • Compound 73
  • Figure US20110160459A1-20110630-C00101
    • N-(4-chlorobenzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.9 Hz, 3H), 1.16-1.32 (m, 4H), 1.52-1.67 (m, 2H), 2.83 (dd, J=17.3 and 13.7 Hz, 1H), 2.88-3.01 (m, 2H), 3.50 (dd, J=17.4 and 11.4 Hz, 1H), 4.46-4.55 (m, 2H), 4.78 (dd, J=13.8 and 11.4 Hz, 1H), 6.95 (br t, J=6.3 Hz, 1H), 7.02-7.09 (m, 1H), 7.12-7.19 (m, 1H), 7.24-7.34 (m, 5H), 7.46 (tt, J=7.5 and 2 Hz, 1H).
  • Compound 74
  • Figure US20110160459A1-20110630-C00102
    • N-(1-Phenyl-ethyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (1:1 diasteromeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.80-0.90 (m, 3H), 1.17-1.33 (m, 4H), 1.53-1.70 (m, 5H), 2.73-2.87 (m, 1H), 2.88-3.02 (m, 2H), 3.42-3.54 (m, 1H), 4.69-4.80 (m, 1H), 5.20 (quintet, J=7.3 Hz, 1H), 6.85 (br d, J=8.4 Hz, 1H), 7.01-7.08 (m, 1H), 7.11-7.19 (m, 1H), 7.23-7.31 (m, 2H), 7.32-7.41 (m, 4H), 7.43-7.51 (m, 1H).
  • Compound 75
  • Figure US20110160459A1-20110630-C00103
    • N-(Adamantylmethyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84-0.89 (m, 3H), 1.21-1.35 (m, 4H), 1.51-1.57 (m, 6H), 1.57-1.77 (m, 6H), 2.00 (br s, 3H), 2.81 (dd, J=17.4 and 13.8 Hz, 1H), 2.90-3.10 (m, 4H), 3.49 (dd, J=17.1 and 11.4 Hz, 1H), 4.75 (dd, J=14 and 11.23 Hz, 1H), 6.69 (t, J=6.8 Hz, 1H), 7.02-7.08 (m, 1H), 7.16 (br t, J=8, 1 H), 7.24-7.31 (m, 1H), 7.49 (dt, J=7.4 and 2 Hz, 1H).
  • Compound 76
  • Figure US20110160459A1-20110630-C00104
    • N-(3,4-Dimethoxybenzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.9 Hz, 3H), 1.15-1.32 (m, 4H), 1.54-1.66 (m, 2H), 2.83 (dd, J=17.1 and 13.8 Hz, 1H), 2.86-3.00 (m, 2H), 3.51 (dd, J=17.3 and 11.6 Hz, 1H), 3.88 (s, 3H), 3.89 (s, 3H), 4.43-4.52 (m, 2H), 4.76 (dd, J=14 and 11.6 Hz, 1H), 6.82-6.92 (m, 4H), 7.03-7.09 (m, 1H), 7.16 (t, J=7.2 Hz, 1H), 7.25-7.32 (m, 1H), 7.47 (dt, J=7.5 and 2 Hz, 1H).
  • Compound 77
  • Figure US20110160459A1-20110630-C00105
    • N-(3-Fluorobenzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ0.82-0.88 (m, 3H), 1.17-1.33 (m, 4H), 1.53-1.71 (m, 2H), 2.84 (dd, J=17.3 and 13.7 Hz, 1H), 2.90-3.03 (m, 2H), 3.51 (dd, J=17.3 and 11.6 Hz, 1H), 4.48-4.58 (m, 2H), 4.79 (dd, J=13.8 and 11.4 Hz, 1H), 6.93-7.02 (m, 2H), 7.02-7.13 (m, 3H), 7.16 (t, J=7.5 Hz, 1H), 7.25-7.35 (m, 2H), 7.47 (dt, J=7.5 and 2 Hz, 1H).
  • Compound 78
  • Figure US20110160459A1-20110630-C00106
    • N-(2-Phenyl-propyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (1:1 diasteromeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7 Hz, 3H), 1.17-1.30 (m, 4H), 1.32 (d, J=6.9 Hz, 3H), 1.52-1.63 (m, 2H), 2.72-3.06 (m, 4H), 3.34-3.51 (m, 2H), 3.58-3.67 (m, 1H), 4.65-4.76 (m, 1H), 6.57 (br t, J=6.3 Hz, 1H), 7.04 (dd, J=9.8 and 8.9 Hz, 1H), 7.11-7.17 (m, 1H), 7.21-7.30 (m, 4H), 7.30-7.36 (m, 2H), 7.42-7.49 (m, 1H).
  • Compound 79
  • Figure US20110160459A1-20110630-C00107
    • N-[2-(7-methyl-indol-3-yl)ethyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=6.9 Hz, 3H), 1.18-1.31 (m, 4H), 1.53-1.65 (m, 2H), 2.49 (s, 3H), 2.80 (dd, J=17.1 and 13.8 Hz, 1H), 2.83-2.97 (m, 2 H), 3.03 (t, J=7.1 Hz, 2H), 3.48 (dd, J=17.1 and 11.4 Hz, 1H), 3.68 (q, J=6.9 Hz, 2H), 4.72 (dd, J=13.8 and 11.4 Hz, 1H), 6.78 (t, J=6.2 Hz, 1H), 6.99-7.09 (m, 4H), 7.15 (t, J=7.5 Hz, 1H), 7.24-7.31 (m, 1H), 7.46 (dt, J=7.5 and 2 Hz, 1H), 7.50 (d, J=7.8 Hz, 1 H), 8.10 (br s, 1H).
  • Compound 80
  • Figure US20110160459A1-20110630-C00108
    • N-(3,4,5-Trimethoxybenzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.9 Hz, 3H), 1.18-1.31 (m, 4H), 1.55-1.66 (m, 2H), 2.84 (dd, J=17.3 and 13.7 Hz, 1H), 2.89-3.01 (m, 2H), 3.52 (dd, J=17.3 and 11.6 Hz, 1H), 3.84 (s, 3H), 3.87 (s, 6H), 4.42-4.52 (m, 2H), 4.78 (dd, J=13.8 and 11.4 Hz, 1H), 6.57 (s, 2H), 6.91 (br t, J=6.2 Hz, 1H), 7.06 (dd, J=9.6 and 8.7 Hz, 1H), 7.16 (t, J=7.5 Hz, 1H), 7.25-7.32 (m, 1H), 7.44-7.50 (m, 1H).
  • Compound 81
  • Figure US20110160459A1-20110630-C00109
    • N-(Cyclooctyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=6.92 Hz, 3H), 1.18-1.34 (m, 4H), 1.50-1.75 (m, 14H), 1.82-1.95 (m, 2H), 2.79 (dd, J=17.4 and 13.8 Hz, 1H), 2.87-3.02 (m, 2H), 3.47 (dd, J=17.3 and 11.3 Hz, 1H), 4.01-4.11 (m, 1H), 4.72 (dd, J=14 and 11.3 Hz, 1H), 6.57 (br d, J=8.4 Hz, 1H), 7.01-7.09 (m, 1H), 7.12-7.18 (m, 1H), 7.24-7.31 (m, 1H), 7.45-7.51 (m, 1H).
  • Compound 82
  • Figure US20110160459A1-20110630-C00110
    • N-(tert-Butyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7.2 Hz, 3H), 1.20-1.33 (m, 4H), 1.42 (s, 9H), 1.56-1.68 (m, 2H), 2.77 (dd, J=17.1 and 13.8 Hz, 1H), 2.92 (br t, J=7.1 Hz, 2H), 3.45 (dd, J=17.3 and 11.3 Hz, 1H), 4.70 (dd, J=14 and 11.3 Hz, 1H), 6.50 (br s, 1H), 7.01-7.08 (m, 1H), 7.12-7.18 (m, 1H), 7.24-7.31 (m, 1H), 7.48 (dt, J=7.5 and 1.8 Hz, 1H).
  • Compound 83
  • Figure US20110160459A1-20110630-C00111
    • N-(2-(Trifluoromethyl)benzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=6.9 Hz, 3H), 1.17-1.33 (m, 4H), 1.54-1.70 (m, 2H), 2.83 (dd, J=17.1 and 13.8 Hz, 1H), 2.88-3.02 (m, 2H), 3.50 (dd, J=17.3 and 11.6 Hz, 1H), 4.67-4.82 (m, 3H), 6.99 (br t, J=6.6 Hz, 1H), 7.02-7.09 (m, 1H), 7.15 (t, J=8.1 Hz, 1H), 7.25-7.31 (m, 1H), 7.38 (t, J=7.7 Hz, 1H), 7.46 (dt, J=7.5 and 1.8 Hz, 1H), 7.54 (t, J=7.7 Hz, 1H), 7.60-7.68 (m, 2H).
  • Compound 84
  • Figure US20110160459A1-20110630-C00112
    • N-(5-Methyl-thiazol-2-yl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85-0.89 (m, 3H), 1.19-1.34 (m, 4H), 1.59-1.69 (m, 2H), 2.40 (s, 3H), 2.93 (dd, J=17 and 13.1 Hz, 1H), 2.97-3.14 (m, 2 H), 3.56 (dd, J=17.1 and 12.3 Hz, 1H), 4.96 (t, J=12.6 Hz, 1H), 7.05-7.12 (m, 2H), 7.18 (t, J=7.4 Hz, 1H), 7.28-7.34 (m, 1H), 7.43 (dt, J=7.5 and 1.8 Hz, 1H), 10.02 (br s, 1H).
  • Compound 85
  • Figure US20110160459A1-20110630-C00113
    • N-(3-Methoxybenzyl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.84 (t, J=6.9 Hz, 3H), 1.17-1.32 (m, 4H), 1.54-1.68 (m, 2H), 2.83 (dd, J=17.1 and 13.8 Hz, 1H), 2.88-3.00 (m, 2H), 3.51 (dd, J=17.3 and 11.6 Hz, 1H), 3.81 (s, 3H), 4.48-4.57 (m, 2H), 4.76 (dd, J=13.8 and 11.4 Hz, 1H), 6.81-6.85 (m, 1H), 6.87-6.95 (m, 3H), 7.02-7.09 (m, 1H), 7.16 (t, J=6.9 Hz, 1H), 7.24-7.31 (m, 2H), 7.47 (dt, J=7.5 and 1.8 Hz, 1H).
  • Compound 86
  • Figure US20110160459A1-20110630-C00114
    • N-[3-(Trifluoromethyl)benzyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.80-0.88 (m, 3H), 1.16-1.33 (m, 4H), 1.53-1.69 (m, 2H), 2.85 (dd, J=17.3 and 13.7 Hz, 1H), 2.90-3.03 (m, 2H), 3.51 (dd, J=17.1 and 11.7 Hz, 1H), 4.56-4.64 (m, 2H), 4.81 (dd, J=13.8 and 11.7 Hz, 1H), 7.02-7.10 (m, 2H), 7.16 (t, J=7.5 Hz, 1H), 7.25-7.33 (m, 1H), 7.43-7.50 (m, 2H), 7.52-7.57 (m, 2H), 7.58 (br s, 1H).
  • Compound 87
  • Figure US20110160459A1-20110630-C00115
    • N-[(1R,2S,5R)-rel-6,6-dimethylbicyclo[3.1.1.]heptan-2-methyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (mixture of diastereoisomers) (from (−)-cis-myrtanylamine (CAS 38235-68-6))
  • 1H-NMR (400 MHz, CDCl3) δ 0.84-0.93 (m, 4H), 1.06 (s, 3H), 1.21 (d, J=2.4 Hz, 3H), 1.22-1.34 (m, 4H), 1.48-1.69 (m, 3H), 1.82-2.03 (m, 5H), 2.22-2.32 (m, 1H), 2.34-2.42 (m, 1H), 2.75-2.85 (m, 1H), 2.88-3.01 (m, 2H), 3.28-3.41 (m, 2 H), 3.43-3.53 (m, 1H), 4.74 (dd, J=13.8 and 11.4 Hz, 1H), 6.64 (br t, J=6.3 Hz, 1H), 7.02-7.08 (m, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.24-7.31 (m, 1H), 7.45-7.51 (m, 1H).
  • Compound 88
  • Figure US20110160459A1-20110630-C00116
    • N-(Adamant-1-yl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7.1 Hz, 3H), 1.18-1.35 (m, 4H), 1.52-1.75 (m, 8H), 2.05-2.13 (m, 9H), 2.75 (dd, J=17.3 and 14 Hz, 1H), 2.92 (t, J=7.4 Hz, 2H), 3.44 (dd, J=17.3 and 11.3 Hz, 1H), 4.69 (dd, J=14 and 11.3 Hz, 1H), 6.39 (br s, 1H), 7.01-7.08 (m, 1H), 7.15 (t, J=7.4 Hz, 1H), 7.23-7.31 (m, 1H), 7.45-7.51 (m, 1H).
  • Compound 89
  • Figure US20110160459A1-20110630-C00117
    • N-[1-phenyl-1-methyl-ethyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ0.86 (t, J=6.9 Hz, 3H), 1.19-1.35 (m, 4H), 1.55-1.70 (m, 2H), 1.76 (s, 3H), 1.77 (s, 3H), 2.76 (dd, J=17.5 and 13.8 Hz, 1H), 2.91-2.99 (m, 2H), 3.42 (dd, J=17.3 and 11.3 Hz, 1H), 4.72 (dd, J=14 and 11.3 Hz, 1 H), 6.96 (br s, 1H), 7.01-7.07 (m, 1H), 7.15 (t, J=7.4 Hz, 1H), 7.20-7.30 (m, 2H), 7.34 (t, J=7.7 Hz, 2H), 7.42-7.52 (m, 3H).
  • Compound 90
  • Figure US20110160459A1-20110630-C00118
    • N-[4-(Trifluoromethyl)benzyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ0.85 (t, J=6.9 Hz, 3H), 1.15-1.34 (m, 4H), 1.53-1.69 (m, 2H), 2.85 (dd, J=17.3 and 13.7 Hz, 1H), 2.90-3.03 (m, 2H), 3.51 (dd, J=17.3 and 11.6 Hz, 1H), 4.54-4.64 (m, 2H), 4.79 (dd, J=13.8 and 11.4 Hz, 1H), 6.98-7.10 (m, 2H), 7.16 (t, J=7.5 Hz, 1H), 7.24-7.33 (m, 1H), 7.43-7.50 (m, 3H), 7.60 (d, J=8.1 Hz, 2H).
  • Compound 91
  • Figure US20110160459A1-20110630-C00119
    • N-[1-(Adamant-1-yl)-ethyl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.83-0.90 (m, 3H), 1.06-1.13 (m, 3H), 1.20-1.36 (m, 4H), 1.49-1.77 (m, 14H), 1.98-2.04 (m, 3H), 2.81 (dd, J=17.3 and 14 Hz, 1H), 2.89-3.03 (m, 2H), 3.49 (dd, J=17.1 and 11.1 Hz, 1H), 3.72-3.82 (m, 1H), 4.68-4.79 (m, 1H), 6.51 (br d, J=10.2 Hz, 1H), 7.01-7.09 (m, 1H), 7.12-7.19 (m, 1 H), 7.24-7.31 (m, 1H), 7.46-7.55 (m, 1H).
  • Compound 92
  • Figure US20110160459A1-20110630-C00120
    • N-(Noradamant-1-yl)-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.83-0.90 (m, 3H), 1.17-1.35 (m, 4H), 1.51-1.71 (m, 6H), 1.91-1.98 (m, 2H), 2.01-2.10 (m, 2H), 2.10-2.19 (m, 2H), 2.29 (br s, 2H), 2.50 (br t, J=6.8 Hz, 1H), 2.79 (dd, J=17.4 and 13.8 Hz, 1H), 2.93 (t, J=7.2 Hz, 2H), 3.46 (dd, J=17.3 and 11.3 Hz, 1H), 4.72 (dd, J=14 and 11.3 Hz, 1H), 6.79 (br s, 1H), 7.05 (ddd, J=10.2, 8.1 and 1.2 Hz, 1H), 7.15 (br t, J=6.9 Hz, 1H), 7.24-7.32 (m, 1H), 7.48 (dt, J=7.5 and 2.1 Hz, 1H).
  • Compound 93
  • Figure US20110160459A1-20110630-C00121
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-(benzothien-3-yl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 1)
  • Compounds 93 and 94 were obtained from the corresponding diasteromeric mixture via a Sepacore column (40×150 mm) chromatographic purification. Eluant gradient: petroleum ether (40-60)/diethyl ether=90/10=>petroleum ether (40-60)/diethyl ether=80/20 (v/v)). Compound 93: first (fastest) eluting diastereomer: Compound 94: second (slowest) eluting diastereomer:
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-1.02, (m, 13H), 1.20-1.49 (m, 4H), 1.59-1.67 (m, 3H), 1.70 (t, J=4.5 Hz, 1H), 1.75-1.87 (m, 1H), 2.38 (m, 1H), 2.91-3.11 (m, 3H), 3.51 (dd, J=17.4 and 11.4 Hz, 1H), 4.38-4.48 (m, 1H), 4.80 (dd, J=14.4 and 11.4 Hz, 1H), 6.71 (br d, J=9.3 Hz, 1H), 7.37 (dd, J=6.2 and 3.2 Hz, 2H), 7.40 (s, 1H), 7.75-7.81 (m, 1H), 7.86-7.91 (m, 1H).
  • Compound 94
  • Figure US20110160459A1-20110630-C00122
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-(benzothien-3-yl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 2)
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-1.03 (m, 13H), 1.20-1.51 (m, 4H). 1.62-1.68 (m, 3H), 1.70 (t, J=4.4 Hz, 1H), 1.76-1.88 (m, 1H), 2.34-2.47 (m, 1H), 2.90-3.11 (m, 3H), 3.50 (dd, J=17.3 and 11.3 Hz, 1H), 4.27-4.37 (m, 1H), 4.78 (dd, J=14.4 and 11.4 Hz, 1H), 6.71 (br d, J=9 Hz, 1H), 7.35-7.45 (m, 3H), 7.77-7.83 (m, 1H), 7.86-7.92 (m, 1H).
  • Compound 95
  • Figure US20110160459A1-20110630-C00123
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-pentyl)-5-(thien-3-yl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.83-0.93 (m, 10H), 0.97 (s, 3H), 1.20-1.34 (m, 5H), 1.36-1.46 (m, 1H), 1.54-1.65 (m, 3H), 1.69 (t, J=4.5 Hz, 1H), 1.73-1.86 (m, 1H), 2.32-2.42 (m, 1H), 2.80-2.90 (m, 1H), 2.90-3.04 (m, 2H), 3.31-3.41 (m, 1H), 4.26-4.34 (m, 1H), 4.46-4.56 (m, 1H), 6.66 (br d, J=9 Hz, 1H), 7.08-7.13 (m, 1H), 7.18-7.22 (m, 1H), 7.31-7.35 (m, 1H).
  • Compound 96
  • Figure US20110160459A1-20110630-C00124
    • N-(1-phenyl-1-methyl-ethyl)-1-(n-pentyl)-5-(thien-3-yl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.83-0.90 (m, 3H), 1.20-1.33 (m, 4H), 1.53-1.68 (m, 2H), 1.76 (s, 3H), 1.77 (s, 3H), 2.80 (dd, J=17.1 and 14.1 Hz, 1H), 2.87-3.01 (m, 2H), 3.29 (dd, J=17.1 and 10.8 Hz, 1H), 4.49 (dd, J=14.1 and 10.8 Hz, 1H), 6.96 (br s, 1H), 7.08-7.12 (m, 1H), 7.18-7.21 (m, 1H), 7.23 (br t, J=7.2 Hz, 1 H), 7.30-7.38 (m, 3H), 7.45 (br d, J=7.2 Hz, 2H).
  • Compound 97
  • Figure US20110160459A1-20110630-C00125
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-propyl)-5-(3-(trifluoromethyl)phenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 1)
  • Compounds 97 and 98 were obtained from the corresponding diasteromeric mixture via a Sepacore column (40×150 mm) chromatographic purification. Eluant gradient: petroleum ether (40-60)/diethyl ether=90/10=>petroleum ether (40-60)/diethyl ether=60/40 (v/v)). Compound 97: second (slowest) eluting diastereomer: Compound 98: first (fastest) eluting diastereomer.
  • 1H-NMR (400 MHz, CDCl3) δ 0.84-0.93 (m, 10H), 0.97 (s, 3H), 1.21-1.30 (m, 1H), 1.38-1.47 (m, 1H), 1.56-1.68 (m, 3H), 1.70 (t, J=4.4 Hz, 1H), 1.76-1.86 (m, 1H), 2.33-2.43 (m, 1H), 2.80 (dd, J=17.4 and 14.4 Hz, 1H), 2.82-2.98 (m, 2 H), 3.46 (dd, J=17.4 and 11.1 Hz, 1H), 4.26-4.34 (m, 1H), 4.45 (dd, J=14.4 and 11.1 Hz, 1H), 6.67 (br d, J=9.1 Hz, 1H), 7.46-7.51 (m, 1H), 7.55-7.61 (m, 2H), 7.67 (br s, 1H).
  • Compound 98
  • Figure US20110160459A1-20110630-C00126
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-propyl)-5-(3-(trifluoromethyl)phenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 2)
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.94 (m, 10H), 0.97 (s, 3H), 1.20-1.35 (m, 1H), 1.38-1.48 (m, 1H), 1.54-1.67 (m, 3H), 1.69 (t, J=4.4 Hz, 1H), 1.75-1.86 (m, 1H), 2.33-2.42 (m, 1H), 2.79 (dd, J=17.3 and 14.3 Hz, 1H), 2.85-3.00 (m, 2 H), 3.48 (dd, J=17.4 and 11.4 Hz, 1H), 4.25-4.35 (m, 1H), 4.47 (dd, J=14.1 and 11.1 Hz, 1H), 6.68 (br d, J=9.1 Hz, 1H), 7.46-7.51 (m, 1H), 7.55-7.60 (m, 2H), 7.65 (br s, 1H).
  • Compound 99
  • Figure US20110160459A1-20110630-C00127
    • N-(1-phenyl-1-methyl-ethyl)-1-(n-propyl)-5-(3-(trifluoromethyl)phenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.88 (t, J=7.4 Hz, 3H), 1.55-1.71 (m, 2H), 1.76 (s, 3H), 1.77 (s, 3H), 2.75 (dd, J=17.4 and 14.4 Hz, 1H), 2.80-2.98 (m, 2H), 3.41 (dd, J=17.4 and 11.1 Hz, 1H), 4.44 (dd, J=14.4 and 11.1 Hz, 1H), 6.97 (br s, 1H), 7.21-7.27 (m, 1H), 7.35 (br t, J=7.7 Hz, 2H), 7.43-7.52 (m, 3H), 7.55-7.60 (m, 2H), 7.65 (br s, 1H).
  • Compound 100
  • Figure US20110160459A1-20110630-C00128
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-pentyl)-5-(3-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (1:1 diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.94 (m, 10H), 0.97 (s, 3H), 1.20-1.35 (m, 5H), 1.37-1.47 (m, 1H), 1.54-1.65 (m, 3H), 1.67-1.72 (m, 1H), 1.75-1.87 (m, 1H), 2.32-2.42 (m, 1H), 2.73-2.84 (m, 1H), 2.91-2.99 (m, 2H), 3.38-3.49 (m, 1 H), 4.26-4.45 (m, 2H), 6.66 (br d, J=6.6 Hz, 1H), 7.00 (dt, J=8.4 and 2.4 Hz, 1H), 7.08-7.17 (m, 2H), 7.28-7.35 (m, 1H).
  • Compound 101
  • Figure US20110160459A1-20110630-C00129
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-pentyl)-5-(2-fluorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • To a magnetically stirred solution of E-2-oxo-4-(2-fluorophenyl)-but-3-enoic acid [endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamide] (Intermediate X-3) (1.5 g, 4.83 mmol) in ethanol (50 ml) was successively added acetic acid (660 ml, 11.58 mmol) and n-pentylhydrazine (Intermediate XI-1) (1.45 ml, 9.65 mmol) and the resulting mixture was reacted in a nitrogen atmosphere at 60° C. for 8 hours in an oil bath. The reaction mixture was allowed to attain room temperature and concentrated in vacuo. The residue was dissolved in dichloromethane, washed with water and subsequently dried over MgSO4, filtered and concentrated in vacuo. Further chromatographic purification using Sepacore equipment (eluant: petroleum ether/ethylacetate=95/5 (v/v)) gave compound 101 (940 mg, 46% yield) as an oil. 1H-NMR (400 MHz, CDCl3) δ 0.83-0.94 (m, 10H), 1.20-1.85 (m, 14H), 2.32-2.42 (m, 1H), 2.74-2.85 (m, 1H), 2.91-3.02 (m, 2H), 3.43-3.54 (m, 1H), 4.26-4.36 (m, 1H), 4.69-4.80 (m, 1H), 6.63-6.70 (m, 1H), 7.02-7.09 (m, 1H), 7.12-7.19 (m, 1H), 7.25-7.31 (m, 1H), 7.46-7.54 (m, 1H).
  • Compound 102
  • Figure US20110160459A1-20110630-C00130
    • N-(1-phenyl-1-methyl-ethyl)-1-(n-butyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • Compound 102 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [1-phenyl-1-methyl-ethyl]amide and n-butylhydrazine analogously to the procedure described for compound 101. 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7, 3H), 1.20-1.39 (m, 2H), 1.53-1.63 (m, 2H), 1.76 (s, 3H), 1.77 (s, 3H), 2.77 (dd, J=17 and 14, 1H), 2.90-2.96 (m, 2H), 3.35 (dd, J=17 and 11, 1 H), 4.37 (dd, J=14 and 11, 1 H), 6.97 (br s, 1H), 7.21-7.48 (m, 10H).
  • Compound 103
  • Figure US20110160459A1-20110630-C00131
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • Compound 103 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamide] (Intermediate X-2) and n-butylhydrazine analogously to the procedure described for compound 101. 1H-NMR (400 MHz, CDCl3) δ 0.83-0.95 (m, 10H), 0.97 (s, 3H), 1.21-1.86 (m, 9H), 2.32-2.42 (m, 1H), 2.77-2.88 (m, 1H), 2.91-2.99 (m, 2H), 3.35-3.46 (m, 1H), 4.26-4.46 (m, 2H), 6.66 (br d, J˜8, 1 H), 7.28-7.40 (m, 5H).
  • Compound 104
  • Figure US20110160459A1-20110630-C00132
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • Compound 104 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-ylamide] (Intermediate X-2) and n-pentylhydrazine (Intermediate XI-1) analogously to the procedure described for compound 101. 1H-NMR (400 MHz, CDCl3) δ 0.83-0.94 (m, 10H), 0.97 (s, 3H), 1.20-1.47 (m, 5H), 1.54-1.65 (m, 3H), 1.69 (t, J ˜6, 1 H), 1.75-1.85 (m, 1H), 2.32-2.42 (m, 1H), 2.82 (dd, J=17 and 14, 1H), 2.92-2.98 (m, 2H), 3.41 (dd, J=17 and 11, 1H), 4.26-4.35 (m, 1H), 4.41 (dd, J=14 and 11, 1 H), 6.67 (br d, J˜8, 1 H), 7.28-7.39 (m, 5H).
  • Compound 105
  • Figure US20110160459A1-20110630-C00133
    • N-(1-(4-fluorophenyl)-1-methyl-ethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • Compound 6 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [1-(4-fluorophenyl)-1-methyl-ethyl]amide and n-pentylhydrazine (Intermediate XI-1) analogously to the method described for compound 101. 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7, 3H), 1.20-1.31 (m, 4H), 1.54-1.67 (m, 2H), 1.74 (s, 3H), 1.75 (s, 3H), 2.77 (dd, J=17 and 14, 1H), 2.90-2.97 (m, 2H), 3.35 (dd, J=17 and 11, 1H), 4.38 (dd, J=14 and 11, 1H), 6.94 (br s, 1H), 6.98-7.04 (m, 2H), 7.27-7.43 (m, 7H).
  • Compound 106
  • Figure US20110160459A1-20110630-C00134
    • N-(2-(4-fluorophenyl)-1,1-dimethyl-ethyl)-1-(n-pentyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • Compound 106 was obtained from E-2-oxo-4-phenyl-but-3-enoic acid [2-(4-fluorophenyl)-2,2-dimethyl-ethyl]amide (Intermediate X-4) and n-pentylhydrazine (Intermediate XI-1) analogously to the procedure described for compound 101. 1H-NMR (400 MHz, CDCl3) δ 0.85 (t, J=7, 3H), 1.16-1.27 (m, 4H), 1.36 (s, 3H), 1.39 (s, 3H), 1.50-1.62 (m, 2H), 2.77-2.94 (m, 4H), 3.04 (d, J=13, 1H), 3.10 (d, J=13, 1H), 3.41 (dd, J=18 and 12, 1 H), 4.39 (dd, J=14 and 11, 1 H), 6.38 (br s, 1H), 6.94-7.01 (m, 2H), 7.10-7.16 (m, 2H), 7.28-7.38 (m, 5H).
  • Furthermore, the compounds 107-118 were obtained analogously to the method described for compound 101.
  • Compound 107
  • Figure US20110160459A1-20110630-C00135
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-isobutyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85 (d, J=6.6 Hz, 3H), 0.88 (d, J=6.6 Hz, 3 H), 1.73 (s, 3H), 1.75 (s, 3H), 1.96-2.07 (m, 1H), 2.54 (dd, J=12.6 and 9 Hz, 1H), 2.77 (dd, J=17.4 and 14.1 Hz, 1H), 2.84 (dd, J=12.6 and 5.1 Hz, 1H), 3.34 (dd, J=17.4 and 11.1 Hz, 1H), 4.34 (dd, J=14.4 and 11.1 Hz, 1H), 6.93 (br s, 1H), 7.01 (t, J=8.9 Hz, 2H), 7.27-7.37 (m, 5H), 7.38-7.44 (m, 2H).
  • Compound 108
  • Figure US20110160459A1-20110630-C00136
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-cyclohexylmethyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.67-0.90 (m, 2H), 1.05-1.29 (m, 4H), 1.51-1.72 (m, 4H), 1.74 (s, 3H), 1.75 (s, 3H), 1.82-1.90 (m, 1H), 2.61 (dd, J=12.8 and 8.9 Hz, 1H), 2.76 (dd, J=17.3 and 14.3 Hz, 1H), 2.83 (dd, J=12.6 and 5.1 Hz, 1H), 3.33 (dd, J=17.3 and 11 Hz, 1H), 4.33 (dd, J=14.4 and 11.1 Hz, 1H), 6.93 (br s, 1H), 7.01 (t, J=8.7 Hz, 2H), 7.27-7.37 (m, 5H), 7.39-7.43 (m, 2H).
  • Compound 109
  • Figure US20110160459A1-20110630-C00137
    • N-[1-(4-fluorophenyl)-1-methyl-ethyl]-1-phenethyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 1.74 (s, 3H), 1.75 (s, 3H), 2.77 (dd, J=17.4 and 14.4 Hz, 1H), 2.84-2.93 (m, 1H), 2.95-3.03 (m, 1H), 3.13-3.29 (m, 2H), 3.33 (dd, J=17.4 and 11.1 Hz, 1H), 4.43 (dd, J=14.4 and 11.1 Hz, 1H), 6.91 (br s, 1H), 7.02 (t, J=8.7 Hz, 2H), 7.14 (d, J=6.9 Hz, 2H), 7.16-7.35 (m, 8H), 7.38-7.44 (m, 2H).
  • Compound 110
  • Figure US20110160459A1-20110630-C00138
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-isobutyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, DMSO-d6) δ 0.81-0.95 (m, 13H), 0.96 (s, 3H), 1.22-1.30 (m, 1H), 1.37-1.47 (m, 1H), 1.55-1.67 (m, 1H), 1.69 (t, J=4.5 Hz, 1H), 1.75-1.85 (m, 1H), 1.96-2.08 (m, 1H), 2.32-2.43 (m, 1H), 2.52-2.60 (m, 1H), 2.78-2.88 (m, 2H), 3.36-3.46 (m, 1H), 4.26-4.41 (m, 2H), 6.67 (br d, J=8 Hz, 1H), 7.27-7.40 (m, 5H).
  • Compound 111
  • Figure US20110160459A1-20110630-C00139
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-cyclohexylmethyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, DMSO-d6) δ 0.70-0.95 (m, 9H), 0.98 (s, 3H), 1.04-1.32 (m, 5H), 1.37-1.48 (m, 1H), 1.55-1.90 (m, 8H), 2.32-2.43 (m, 1H), 2.60-2.70 (m, 1H), 2.77-2.89 (m, 2H), 3.35-3.46 (m, 1H), 4.26-4.42 (m, 2H), 6.65 (br d, J=9 Hz, 1H), 7.27-7.39 (m, 5H).
  • Compound 112
  • Figure US20110160459A1-20110630-C00140
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(2-cyano-ethyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, DMSO-d6) δ 0.82-0.95 (m, 7H), 0.97 (s, 3H), 1.22-1.32 (m, 1H), 1.38-1.49 (m, 1H), 1.54-1.65 (m, 1H), 1.70 (t, J=4.7 Hz, 1H), 1.75-1.88 (m, 1H), 2.34-2.44 (m, 1H), 2.61-2.77 (m, 2H), 2.88 (dd, J=17.6 and 14.3 Hz, 1 H), 3.20 (t, J=6.8 Hz, 2H), 3.46 (dd, J=17.4 and 10.8 Hz, 1H), 4.26-4.35 (m, 1H), 4.39 (dd, J=14.4 and 10.8 Hz, 1H), 6.67 (br d, J=9 Hz, 1H), 7.31-7.44 (m, 5H).
  • Compound 113
  • Figure US20110160459A1-20110630-C00141
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-phenethyl-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomeric mixture)
  • 1H-NMR (400 MHz, DMSO-d6) δ 0.85-0.96 (m, 7H), 0.98 (s, 3H), 1.20-1.32 (m, 1H), 1.39-1.48 (m, 1H), 1.55-1.65 (m, 1H) 1.70 (t, J=4.5 Hz, 1H), 1.76-1.88 (m, 1H) 2.33-2.43 (m, 1H), 2.77-2.93 (m, 2H), 2.95-3.04 (m, 1H), 3.16-3.30 (m, 2H), 3.42 (dd, J=17.4 and 11.1 Hz, 1H), 4.26-4.35 (m, 1H), 4.45 (dd, J=14.4 and 11.1 Hz, 1H), 6.65 (br d, J=9.3 Hz, 1H), 7.10-7.40 (m, 10H).
  • Compound 114
  • Figure US20110160459A1-20110630-C00142
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-(4-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 1)
  • Compounds 114 and 115 were obtained from the corresponding diasteromeric mixture via a flash chromatographic purification. Eluant: petroleum ether (40-60)/diethyl ether=75/25. Compound 115: first (fastest) eluting diastereomer): Compound 114: second (slowest) eluting diastereomer.
  • 1H-NMR (400 MHz, CDCl3) δ 0.81-0.93 (m, 10H), 0.97 (s, 3H), 1.08-1.65 (m, 7H), 1.69 (t, J=4.5 Hz, 1H), 1.74-1.85 (m, 1H), 2.33-2.42 (m, 1H), 2.78 (dd, J=17.1 and 14.4 Hz, 1H), 2.92 (t, J=7.4 Hz, 2H), 3.40 (dd, J=17.4 and 11.1 Hz, 1H), 4.26-4.34 (m, 1H), 4.36 (dd, J=14.4 and 11.1 Hz, 1H), 6.65 (br d, J=9.3 Hz, 1H), 7.33 (s, 4H).
  • Compound 115
  • Figure US20110160459A1-20110630-C00143
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-(4-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (diastereomer 2)
  • 1H-NMR (400 MHz, CDCl3) δ 0.82-0.93 (m, 10H), 0.97 (s, 3H), 1.18-1.63 (m, 7H), 1.69 (t, J=4.5 Hz, 1H), 1.75-1.85 (m, 1H), 2.32-2.42 (m, 1H), 2.77 (dd, J=17.3 and 14.3 Hz, 1H), 2.93 (t, J=7.4 Hz, 2H), 3.37-3.46 (m, 1H), 4.26-4.34 (m, 1H), 4.38 (dd, J=14.1 and 11.1 Hz, 1H), 6.66 (br d, J=9.3 Hz, 1H), 7.29-7.35 (m, 4H).
  • Compound 116
  • Figure US20110160459A1-20110630-C00144
    • N-[1-phenyl-1-methyl-ethyl]-1-n-butyl-5-(4-chlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.86 (t, J=7.4 Hz, 3H), 1.20-1.38 (m, 2H), 1.53-1.63 (m, 2H), 1.76 (s, 3H), 1.77 (s, 3H), 2/2 (dd, J=17.3 and 14.3 Hz, 1H), 2.90 (t, J=7.4 Hz, 2H), 3.34 (dd, J=17.4 and 11.1 Hz, 1H), 4.34 (dd, J=14.4 and 11.1 Hz, 1H), 6.95 (br s, 1H), 7.20-7.26 (m, 1H), 7.28-7.37 (m, 6H), 7.45 (d, J=7.8 Hz, 2H).
  • Compound 117
  • Figure US20110160459A1-20110630-C00145
    • N-(1-(4-fluorophenyl)-1-methyl-ethyl)-1-(n-butyl)-5-(3-methoxyphenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide
  • 1H-NMR (400 MHz, CDCl3) δ 0.85-0.89 (m, 3H), 122-1.39 (m, 2H), 1.55-1.66 (m, 2H), 1.73 (s, 3H), 1.74 (s, 3H), 2.76 (dd, J=17.3 and 14.5 Hz, 1H), 2.88-3.01 (m, 2H), 3.33 (dd, J=17.3 and 11.1 Hz, 1H), 3.80 (s, 3H), 4.35 (dd, J=14.5 and 11.1 Hz, 1H), 6.84 (ddd, J=8.12, 2.4 and 1.1 Hz, 1H), 6.91-6.96 (m, 3H), 6.97-7.05 (m, 2H), 7.23-7.28 (m, 1H), 7.38-7.44 (m, 2H).
  • Compound 118
  • Figure US20110160459A1-20110630-C00146
    • N-[endo-(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-1-(n-butyl)-5-(3-methoxyphenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide (1:1 diastereomeric mixture)
  • 1H-NMR (400 MHz, CDCl3) δ 0.84-0.94 (m, 10H), 0.97 (s, 3H), 1.22-1.47 (m, 4H), 1.54-1.66 (m, 3H), 1.69 (t, J=4.4 Hz, 1H), 1.75-1.86 (m, 1H), 2.32-2.43 (m, 1H), 2.76-2.87 (m, 1H), 2.89-3.03 (m, 2H), 3.36-3.45 (m, 1H), 3.81/3.82 (double s, 3H), 4.26-4.43 (m, 2H), 6.63-6.71 (m, 1H), 6.81-6.87 (m, 1H), 6.92-6.97 (m, 2H), 7.23-7.30 (m, 1H).
    • Example 5 Pharmacological Methods In Vitro Affinity for Cannabinoid-CB1 Receptors
  • The affinity of the compounds of the invention for cannabinoid CB1 receptors can be determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabinoid CB1 receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of one or more compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
    • In Vitro Affinity for Cannabinoid-CB2 Receptors
  • The affinity of the compounds of the invention for cannabinoid CB2 receptors can be determined using membrane preparations of CHO cells in which the human cannabinoid CB2 receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of one or more compounds of the invention, separation of bound and free ligand is performed by filtration over glassfiber filters. Radioactivity on the filter is measured by liquid scintillation counting.
    • In Vitro Cannabinoid-CB1 Receptor (Ant)Agonism
  • In vitro CB1 receptor antagonism/agonism can be assessed with the human CB1 receptor cloned in CHO cells. CHO cells are grown in a Dulbecco's Modified Eagle's medium (DMEM) culture medium, supplemented with 10% heat-inactivated fetal calf serum. Medium is aspirated and replaced by DMEM, without fetal calf serum, but containing [3H]-arachidonic acid and incubated overnight in a cell culture stove (5% CO2/95% air; 37° C.; water-saturated atmosphere). During this period [3H]-arachidonic acid is incorporated in membrane phospholipids. On the test day, medium is aspirated and cells are washed three times using 0.5 ml DMEM, containing 0.2% bovine serum albumin (BSA). CB1 agonist stimulation leads to activation of PLA2 followed by release of [3H]-arachidonic acid into the medium. This CB1 agonist-induced release is concentration-dependently antagonized by CB1 receptor antagonists, such as for example rimonabant.
    • In Vitro Cannabinoid-CB2 Receptor (Ant)Agonism
  • Functional activity at the cannabinoid CB2 receptor was assessed using a forskolin-stimulated cAMP accumulation assay. The ability of compounds to stimulate and inhibit adenylate cyclase activity was assessed in Chinese ovarian hamster (CHO) K1 cells expressing human CB2 (Euroscreen, Brussel) receptor. CHO cells were grown in a CHO—S—SFM-II culture medium, supplemented with 10% heat-inactivated foetal calf serum, 2 mM glutamine, 400 μg/ml Hygromycine B and 500 μg/ml G418 at 37° C. in 93% air/5% CO2. For incubation with test compounds, confluent cultures grown in 24 well plates were used. Each condition or substance was routinely tested in quadruplicate. Cells were loaded with 1 mCi [3H]-adenine in 0.5 ml medium per well. After 2 hours, cultures were washed with 0.5 ml PBS containing 1 mM IBMX and incubated for 20 minutes with 0.5 ml PBS containing 1 mM IBMX and 3×10−7M forskolin with or without the test compound. Antagonistic effects of test compounds were determined as inhibition of 0.1 μM JWH-133-decreased [3H]cAMP formation. After aspiration the reaction was stopped with 1 ml trichloroacetic acid (5% w/v). The [3H]-ATP and [3H]-cAMP formed in the cellular extract were assayed as follows: a volume of 0.8 ml of the extract was passed over Dowex (50WX-4200-400 mesh) and aluminum oxide columns, eluted with water and 0.1M imidazole (pH=7.5). Eluates were mixed with 7 ml Ultima-Flo [AP] and the β-radioactivity was counted with a liquid scintillation counter. The conversion of [3H]-ATP into [3H]-cAMP was expressed as the ratio in percentage radioactivity in the cAMP fraction as compared to the combined radioactivity in both cAMP and ATP fractions, and basal activity was subtracted to correct for spontaneous activity. Reference compounds used to assess cannabinoid CB2 receptor mediated adenylate cyclase activity were the full cannabinoid CB2 receptor agonists JWH-133 (Huffman, 1999b) and WIN 55, 212-2 (Huffman, 1999a), and the inverse agonist or antagonist SR-144528 (Rinaldi-Carmona, 1998). Compounds were studied in a concentration range of 10−10 M to 10−6M. pEC50 and the pA2 were calculated according to Cheng-Prusoff equation (Cheng and Prusoff, 1973). Two independent experiments were performed in triplicate.
    • Example 6 Pharmacological Test Results
  • Affinity for Cb1- and CB2- receptors, and in
    vitro agonistic activity on CB1- receptors
    receptor binding Functional CB1 assays
    Human CB1 Human CB2 Human CB1
    affinity affinity agonism
    Cmp pKi pKi pEC50
    1 8.1 8.3 8.1
    4 7.5 7.1 7.4
    7 6.9 6.3 6.2
    12 7.1 7.4 7.4
    14 7.5 6.6 6.3
    22 7.2 6.5 7.1
    27 7.8 8.1 7.9
    28 8.2 7.0 8.1
    32 8.1 8.0 7.4
    37 7.8 7.0 8.1
    101 8.2 8.1 8.2
    102 7.4 7.4 7.0
    103 7.1 7.6 7.5
    104 8.2 7.6 8.5
    105 7.8 6.9 8.8
    108 7.6 7.5 7.8
    110 7.3 7.3 6.5
  • The compounds of the invention have a high affinity for cannabinoid-CB1 and CB2 receptors, and are agonists on CB1 receptors. Surprising, because 1,3,5-trisubstituted pyrazoline derivatives described in e.g., WO 2005/074920, WO 2005/077911 and WO 2007/009689, as cannabinoid CB1 receptor ‘modulating’ agents, a definition embracing agonists, invariably were shown to be antagonists.
    • Example 7 Pharmaceutical Preparations
  • For clinical use, compounds of formula (I) can be formulated into pharmaceutical compositions that are important and novel embodiments of the invention because they contain the compounds, more particularly specific compounds disclosed herein. Types of pharmaceutical compositions that may be used include, but are not limited to, tablets, chewable tablets, capsules (including microcapsules), solutions, parenteral solutions, ointments (creams and gels), suppositories, suspensions, and other types disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The active ingredient, for instance, may also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters. The compositions are used for oral, intravenous, subcutaneous, tracheal, bronchial, intranasal, pulmonary, transdermal, buccal, rectal, parenteral or other ways to administer. The pharmaceutical formulation contains at least one compound of formula (I) in a mixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier. In one embodiment, the total amount of active ingredients may be in amounts, for example, from about 0.1% (w/w) to about 95% (w/w) of the formulation, and from 0.5% to 50% (w/w), and further from 1% to 25% (w/w).
  • The compounds of the invention can be brought into forms suitable for administration by means of usual processes using auxiliary substances such as liquid or solid, powdered ingredients, such as the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavorings, colorings and/or buffer substances. Frequently used auxiliary substances include magnesium carbonate, titanium dioxide, lactose, saccharose, sorbitol, mannitol and other sugars or sugar alcohols, talc, lactoprotein, gelatin, starch, amylopectin, cellulose and its derivatives, animal and vegetable oils such as fish liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture may then be processed into granules or pressed into tablets. A tablet is prepared using the ingredients below:
  • Ingredient Quantity (mg/tablet)
    COMPOUND No. 1 10
    Cellulose, microcrystalline 200
    Silicon dioxide, fumed 10
    Stearic acid 10
    Total 230
  • The components are blended and compressed to form tablets each weighing 230 mg.
  • The active ingredients may be separately premixed with the other non-active ingredients, before being mixed to form a formulation. The active ingredients may also be mixed with each other, before being mixed with the non-active ingredients to form a formulation.
  • Soft gelatin capsules may be prepared with capsules containing a mixture of the active ingredients of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules. Hard gelatin capsules may contain granules of the active ingredients. Hard gelatin capsules may also contain the active ingredients together with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.
  • Dosage units for rectal administration may be prepared (i) in the form of suppositories that contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule that contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
  • Liquid preparations may be prepared in the form of syrups, elixirs, concentrated drops or suspensions, e.g. solutions or suspensions containing the active ingredients and the remainder consisting, for example, of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, preservatives, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations may also be prepared in the form of a dry powder, reconstituted with a suitable solvent prior to use. Solutions for parenteral administration may be prepared as a solution of a formulation of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients, preservatives and/or buffering ingredients. Solutions for parenteral administration may also be prepared as a dry preparation, reconstituted with a suitable solvent before use.
  • Also provided according to the present invention are formulations and ‘kits of parts’ comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention, for use in medical therapy. Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration. The use of formulations of the invention in the manufacture of medicaments for use in the treatment of a condition in which activation of cannabinoid CB1 receptors is required or desired, and methods of medical treatment or comprising the administration of a therapeutically effective total amount of at least one compound of formula (I), to a patient suffering from, or susceptible to, a condition in which activation of cannabinoid CB1 receptors is required or desired.
  • By way of example and not of limitation, several pharmaceutical compositions are given, comprising exemplary active compounds for systemic use or topical application. Other compounds of the invention or combinations thereof, may be used in place of (or in addition to) said compounds. The concentration of the active ingredient may be varied over a wide range as discussed herein. Amounts and types of ingredients that may be included are known in the art.
    • BIBLIOGRAPHY
  • To the extent in which the following references are useful to one skilled in the art, or to more fully describe this invention, they are incorporated herein by reference. Neither these, nor any other documents or quotes cited herein, nor citations to any references, are admitted to be prior art documents or citations.
    • Akaji, K. et al., Tetrahedron Lett., 35, 3315-3318, 1994.
    • Albericio, F., et al., Tetrahedron Lett., 38, 4853-4856, 1997.
    • Annan et al., J. Am. Chem. Soc. 1989, 111, 8895-8901
    • Bach et al., Tetrahedron, 1994, 50, 7543-7556
    • Barnes, M. P., Expert Opin. Pharmacother. 2006, 7, 607-615)
    • Berge, S. M.: “Pharmaceutical salts”, J. Pharmaceutical Science, 66, 1-19 (1977).
    • Bickel, M. H., “The pharmacology and Biochemistry of N-oxides”, Pharmacological Reviews, 21(4), 325-355, 1969.
    • Bodanszky, M. and A. Bodanszky: The Practice of Peptide Synthesis, Springer-Verlag, New York, ISBN: 0-387-57505-7, 1994.
    • Byrn et al., Pharmaceutical Research, 12(7), 945-954, 1995.
    • Chem. Ber. 1965, 98, 1588-1597
    • Cheng, Y. and Prusoff, W. H., Biochem. Pharmacol., 22, 3099-3108, 1973
    • Croxford, J. L., “Therapeutic potential of cannabinoids in CNS disease”, CNS Drugs, 17, 179-202, 2003.
    • Croxford, J. L. and Miller, S. D. “Towards cannabis and cannabinoid treatment of multiple sclerosis”, Drugs Today (Bare), 40, 663-676, 2004.
    • Drysdale, A. J. and Platt, B., “Cannabinoids: mechanisms and therapeutic applications in the CNS”, Curr. Med. Chem., 10, 2719-2732, 2003
    • Dwyer & Meilor: “Chelating agents and Metal Chelates”, Academic Press, chapter 7, 1964.
    • Huffman et al., Curr. Med. Chem., 6, 705-720, 1999a
    • Huffman et al., Bioorg. Med. Chem., 7, 2905-2914, 1999b
    • Hurst, D. P. et al., Mol. Pharmacol., 62, 1274-1287, 2002
    • Lange, J. H. M. and Kruse, C. G. Drug Discov. Today, 10, 693-702, 2005
    • Levin, J. I., Turos, E. and Weinreb, S. M., Synth Commun., 12, 989-993., 1982
    • Ligresti, A., et al., “Possible endocannabinoid control of colorectal cancer growth”, Gastro-enterology, 125, 677-687, 2003.
    • Martin, E. W. (Editor), “Remington: The Science and Practice of Pharmacy”, Mack Publishing Company, 19th Edition, Easton, Pa, Vol 2., Chapter 83, 1447-1462, 1995.
    • Montalbetti, C. A. G. N. & V. Falque, Tetrahedron, 61, 10827-52. 2005.
    • Pertwee, R. G., Life Sci., 76, 1307-1324, 2005
    • Reggio, P. H., Curr. Pharm. Des., 9, 1607-1633, 2003
    • Rinaldi-Carmona et al., J. Pharmacol. Exp. Ther., 284, 644-650, 1998
    • Shim, J., et al., J. Med. Chem., 45, 1447-1459, 2002.
    • Smith, M. B. and March, J., “Advanced organic chemistry, reactions, mechanisms and structure”, fifth edition, John Wiley & Sons, Inc., New York, 2001, p. 275.
    • Smith, P. F., “Medicinal cannabis extracts for the treatment of multiple sclerosis”, Curr. Opin. Investig. Drugs, 5, 727-730, 2004
    • WO 2005/074920, WO 2005/077911 and WO 2007/009689

Claims (4)

1-10. (canceled)
11. A compound of formula (Va):
Figure US20110160459A1-20110630-C00147
or a tautomer, stereoisomer, N-oxide, isotopically-labelled analogue, or a pharmacologically acceptable salt of any of the foregoing,
wherein:
R1 is chosen from:
C3-10 linear alkyl, C4-10 branched alkyl, C4-10 alkenyl, C4-10 alkynyl, C3-10-heteroalkyl, C5-8-cycloalkyl-C1-5-alkyl, and C5-8-heterocycloalkyl-C1-5-alkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino, cyano and fluoro,
aryl-C1-3-alkyl, heteroaryl-C1-3-alkyl, aryl-C1-3-heteroalkyl, and heteroaryl-C1-3-heteroalkyl, wherein the aryl or heteroaryl groups are optionally substituted with 1-5 substituents Y, wherein each Y is the same or different, and is chosen from C1-3-alkyl, C1-3-alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (C1-2)-amido, (C1-3)-alkyl sulfonyl, dimethylsulfamido, C1-3-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, phenyl, and acetyl, and
2-cyano-ethyl;
R2 is chosen from aryl and heteroaryl, each of which may be optionally substituted with 1-5 substituents Y as defined above;
R5 is chosen from hydrogen and C1-2 alkyl, optionally substituted with 1-3 fluorine atoms; and
R6 is chosen from hydrogen and C1-2 alkyl, optionally substituted with 1-3 fluorine atoms; and
R8 is chosen from chloro and OR7, where R7 is C1-3 alkyl;
provided that if R2 is phenyl and R1 is benzyl, then R7 is not ethyl.
12. A compound of formula (VI):
Figure US20110160459A1-20110630-C00148
or a sodium, potassium, lithium, or cesium salt thereof,
wherein:
R1 is chosen from:
C3-10 linear alkyl, C4-10 branched alkyl, C4-10 alkenyl, C4-10 alkynyl, C3-10-heteroalkyl, C5-8-cycloalkyl-C1-5-alkyl, and C5-8-heterocycloalkyl-C1-5-alkyl, each of which may be optionally substituted with 1-5 substituents, wherein the substituents are the same or different, and are chosen from methyl, ethyl, hydroxy, amino, cyano and fluoro,
aryl-C1-3-alkyl, heteroaryl-C1-3-alkyl, aryl-C1-3-heteroalkyl, and heteroaryl-C1-3-heteroalkyl, wherein the aryl or heteroaryl groups are optionally substituted with 1-5 substituents Y, wherein each Y is the same or different, and is chosen from C1-3-alkyl, C1-3-alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (C1-2)-amido, (C1-3)-alkyl sulfonyl, dimethylsulfamido, C1-3-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, phenyl, and acetyl, and
2-cyano-ethyl;
R2 is chosen from aryl and heteroaryl, each of which may be optionally substituted with 1-5 substituents Y as defined above;
R5 is chosen from hydrogen and C1-2 alkyl, optionally substituted with 1-3 fluorine atoms; and
R6 is chosen from hydrogen and C1-2 alkyl, optionally substituted with 1-3 fluorine atoms;
provided that if R2 is phenyl then R1 is not benzyl.
13. (canceled)
US13/042,620 2007-09-20 2011-03-08 5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists Abandoned US20110160459A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/042,620 US20110160459A1 (en) 2007-09-20 2011-03-08 5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97386307P 2007-09-20 2007-09-20
US12/234,080 US7928134B2 (en) 2007-09-20 2008-09-19 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists
US13/042,620 US20110160459A1 (en) 2007-09-20 2011-03-08 5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/234,080 Division US7928134B2 (en) 2007-09-20 2008-09-19 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists

Publications (1)

Publication Number Publication Date
US20110160459A1 true US20110160459A1 (en) 2011-06-30

Family

ID=40472358

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/234,080 Expired - Fee Related US7928134B2 (en) 2007-09-20 2008-09-19 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists
US13/042,620 Abandoned US20110160459A1 (en) 2007-09-20 2011-03-08 5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/234,080 Expired - Fee Related US7928134B2 (en) 2007-09-20 2008-09-19 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists

Country Status (7)

Country Link
US (2) US7928134B2 (en)
EP (1) EP2203427A2 (en)
KR (1) KR20100072037A (en)
AR (1) AR068464A1 (en)
AU (1) AU2008300631A1 (en)
CA (1) CA2698527A1 (en)
WO (1) WO2009037244A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
WO2018206757A1 (en) * 2017-05-11 2018-11-15 Remynd N.V. Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
DK3621963T3 (en) 2017-05-11 2024-04-15 Remynd N V Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087591A (en) * 1995-04-26 2000-07-11 Nguyen; Phu D. Insulated electrical conductors
FR2742148B1 (en) * 1995-12-08 1999-10-22 Sanofi Sa NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2003512357A (en) * 1999-10-18 2003-04-02 ユニバーシティ オブ コネチカット Pyrazole derivatives as cannabinoid receptor antagonists
JP2005507875A (en) * 2001-08-31 2005-03-24 ユニバーシティ オブ コネチカット Novel pyrazole analogues acting on cannabinoid receptors
MXPA05011922A (en) * 2003-05-07 2006-02-17 Pfizer Prod Inc Cannabinoid receptor ligands and uses thereof.
CA2552940A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments

Also Published As

Publication number Publication date
CA2698527A1 (en) 2009-03-26
AR068464A1 (en) 2009-11-18
US20090082396A1 (en) 2009-03-26
WO2009037244A3 (en) 2009-08-20
WO2009037244A2 (en) 2009-03-26
AU2008300631A8 (en) 2010-04-22
US7928134B2 (en) 2011-04-19
AU2008300631A1 (en) 2009-03-26
KR20100072037A (en) 2010-06-29
EP2203427A2 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
EP1966146B1 (en) 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
EA021755B1 (en) PYRAZINE DERIVATIVES AS ENaC BLOCKERS
KR20070116633A (en) 1-acetic acid-indole derivatives with pgd2 antagonist activity
EP2091939B1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
EP2029548A1 (en) Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
US7928134B2 (en) 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists
US8138174B2 (en) Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
JP2010539214A (en) 5-Aryl-4,5-dihydro- (1H) -pyrazole as a cannabinoid CB1 receptor agonist
US8410135B2 (en) 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
US20110053983A1 (en) (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity
SA06270469B1 (en) 4,5-dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Agonists
US8461184B2 (en) Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
Lange et al. 4, 5 Dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Modulators
AU2008263915A1 (en) 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
KR20090103932A (en) Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition
US20110172274A1 (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity
MX2008008273A (en) 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
TW200916442A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators
SA07280276B1 (en) Sulphur Containing Pyrazole Derivatives as Selective Cannabinoid CB1 Receptor Antagonists

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION